ESC Heart Failure receives its first impact factor
ESC Heart Failure (ESC‐HF) is an open access journal of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) that published its first issue in 2014, with the help of Wiley Publishing. The journal focuses on basic, clinical, and epidemiological heart failure research. Prof. Stefan D. Anker is Editor‐in‐Chief and Deputy Editors are Prof. Zoltán Papp (Basic Science) and Prof. Stephan von Haehling (Clinical). In the first year, ESC‐HF published two issues, which further increased over time to currently six issues per year (2 in 2014, 4 in 2015/2016/2017, 6 in 2018, 6 expected in 2019). Of course, the number of articles published each year also increased during those years (16 in 2014, 39 in 2015, 38 in 2016, 92 in 2017, 147 in 2018, and 135 in the first 4 issues in 2019). In 2019 we expect to publish about 200 articles in ESC‐HF, which is 12 times more than in the beginning year of the journal. We would therefore like to thank all publishing authors that have put their trust into our journal and decided to submit their work to ESC‐HF for review. We would also like to thank all reviewers, statisticians, and associate editors, as well as the editorial board. Special thanks go to our editorial office – Monika Diek, Anja Janssen, and Corinna Denecke – without them it would not be possible to publish ESC‐HF.
Like every year, during summer Thomson Scientific published the new journal impact factors. In Europe and the USA, it is perceived as the most important measure for each journal. Not many people know how this impact factor is calculated: the number of citations of a journal X from the last 2 years are counted for the relevant year and then divided by the number of all original and review articles that were also published in the last 2 years. The formula for calculating the impact factor of journal X in 2018 is shown in Figure.
This year, ESC‐HF received its first impact factor of 3.407, which we think is a great accomplishment, reflecting the hard work everyone involved has put into the journal. If one looks at the best cited papers of the last 3 years, one can see continued interest into the published papers (Tables[[1]] according to Web of Science[76]). Of these articles, already 15 have been cited ≥10 times. Many of them are original articles, but also editorials, short communications and reviews are of great interest for the scientific community.
Top 25 of best cited articles published 2016 in ESC Heart Failure
| Nr. | First author | Title | Type | Times cited | Reference |
|---|
| 1 | Jujo K | Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure | Original research article | 29 | 1 |
| 2 | Konishi M | Heart failure epidemiology and novel treatments in Japan: facts and numbers | Editorial | 23 | 2 |
| 3 | Nagarajan V | Obesity paradox in heart failure: a heavy matter | Review | 16 | 3 |
| 3 | Arrigo M | Effect of precipitating factors of acute heart failure on readmission and long‐term mortality | Original research article | 16 | 4 |
| 3 | Núñez J | Left ventricular ejection fraction recovery in patients with heart failure treated with intravenous iron: a pilot study | Short communication | 16 | 5 |
| 6 | Sotiropoulos K | Red cell distribution width and mortality in acute heart failure patients with preserved and reduced ejection fraction | Original research article | 14 | 6 |
| 7 | Hayashi T | Subclinical hypothyroidism is an independent predictor of adverse cardiovascular outcomes in patients with acute decompensated heart failure | Original research article | 13 | 7 |
| 8 | Sato A | Associations of dipeptidyl peptidase‐4 inhibitors with mortality in hospitalized heart failure patients with diabetes mellitus | Original research article | 10 | 8 |
| 9 | Yoshihisa A | The CHA2DS2‐VASc score as a predictor of high mortality in hospitalized heart failure patients | Original research article | 9 | 9 |
| 9 | Hoshida S | Age‐ and sex‐related differences in diastolic function and cardiac dimensions in a hypertensive population | Original research article | 9 | 10 |
| 11 | Searle J | Acute heart failure facts and numbers: acute heart failure populations | Editorial | 7 | 11 |
| 11 | Thomsen MM | Varying effects of recommended treatments for heart failure with reduced ejection fraction: meta‐analysis of randomized controlled trials in the ESC and ACCF/AHA guidelines | Review | 7 | 12 |
| 11 | Savage HO | Development and validation of a novel non‐contact monitor of nocturnal respiration for identifying sleep‐disordered breathing in patients with heart failure | Original research article | 7 | 13 |
| 11 | Aleksova N | Barriers to goals of care discussions with hospitalized patients with advanced heart failure: feasibility and performance of a novel questionnaire | Original research article | 7 | 14 |
| 15 | Meems LM | Plasma calcidiol, calcitriol, and parathyroid hormone and risk of new onset heart failure in a population‐based cohort study | Original research article | 6 | 15 |
| 15 | Ahmed MB | Higher risk for incident heart failure and cardiovascular mortality among community‐dwelling octogenarians without pneumococcal vaccination | Original research article | 6 | 16 |
| 15 | Yamamoto E | The clinical significance of plasma neopterin in heart failure with preserved left ventricular ejection fraction | Short communication | 6 | 17 |
| 18 | Miller WL | Biomarkers in heart failure: the importance of inconvenient details | Review | 5 | 18 |
| 18 | Yeo TJ | Rationale and design of a pilot randomized controlled trial to assess the role of intravenous ferric carboxymaltose in Asian patients with heart failure (PRACTICE‐ASIA‐HF) | Original research article | 5 | 19 |
| 18 | Olesen LL | ECG as a first step in the detection of left ventricular systolic dysfunction in the elderly | Original research article | 5 | 20 |
| 18 | Ntusi NA | Human immunodeficiency virus‐associated heart failure in sub‐Saharan Africa: evolution in the epidemiology, pathophysiology, and clinical manifestations in the antiretroviral era | Review | 5 | 21 |
| 22 | Kapeller B | Microcurrent stimulation promotes reverse remodelling in cardiomyocytes | Original research article | 4 | 22 |
| 22 | Ortega A | TRPM7 is down‐regulated in both left atria and left ventricle of ischaemic cardiomyopathy patients and highly related to changes in ventricular function | Short communication | 4 | 23 |
| 22 | Okabe T | Steroid pulse therapy was effective for cardiac sarcoidosis with ventricular tachycardia and systolic dysfunction | Case report | 4 | 24 |
| 25 | Pya Y | Initial 3‐year outcomes with left ventricular assist devices in a country with a nascent heart transplantation program | Original research article | 3 | 25 |
Top 25 of best cited articles published 2017 in ESC Heart Failure
| Nr. | First author | Title | Type | Times cited | Reference |
|---|
| 1 | Springer J | Muscle wasting and sarcopenia in heart failure and beyond: update 2017 | Review | 21 | 26 |
| 2 | Luedde M | Heart failure is associated with depletion of core intestinal microbiota | Original research article | 16 | 27 |
| 3 | Riley JP | Palliative care in heart failure: facts and numbers | Editorial | 15 | 28 |
| 3 | Saitoh M | Anorexia, functional capacity, and clinical outcome in patients with chronic heart failure: results from the Studies Investigating Co‐morbidities Aggravating Heart Failure (SICA‐HF) | Original research article | 15 | 29 |
| 5 | Delepaul B | Who are patients classified within the new terminology of heart failure from the 2016 ESC guidelines? | Original research article | 14 | 30 |
| 6 | Barkhudaryan A | Cardiac muscle wasting in individuals with cancer cachexia | Original research article | 11 | 31 |
| 7 | Amin A | On admission serum sodium and uric acid levels predict 30 day rehospitalization or death in patients with acute decompensated heart failure | Original research article | 10 | 32 |
| 8 | Morishita T | Association between matrix metalloproteinase‐9 and worsening heart failure events in patients with chronic heart failure | Original research article | 9 | 33 |
| 8 | Alma LJ | Shared biomarkers between female diastolic heart failure and pre‐eclampsia: a systematic review and meta‐analysis | Review | 9 | 34 |
| 8 | Trippel TD | Ghrelin and hormonal markers under exercise training in patients with heart failure with preserved ejection fraction: results from the Ex‐DHF pilot study | Original research article | 9 | 35 |
| 11 | Khan MS | Renin–angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta‐analysis | Reviews | 8 | 36 |
| 11 | Möckel M | The role of procalcitonin in acute heart failure patients | Review | 8 | 37 |
| 13 | Toma M | Differentiating heart failure phenotypes using sex‐specific transcriptomic and proteomic biomarker panels | Original research article | 7 | 38 |
| 13 | Yoshihisa A | Associations between acylcarnitine to free carnitine ratio and adverse prognosis in heart failure patients with reduced or preserved ejection fraction | Short communication | 7 | 39 |
| 13 | Jaarsma T | Sexual function of patients with heart failure: facts and numbers | Editorial | 7 | 40 |
| 13 | Theidel U | Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany | Original research article | 7 | 41 |
| 17 | Pose A | Benefit of tolvaptan in the management of hyponatraemia in patients with diuretic‐refractory congestive heart failure: the SEMI‐SEC project | Original research article | 6 | 42 |
| 17 | Silvetti S | Rehospitalization after intermittent levosimendan treatment in advanced heart failure patients: a meta‐analysis of randomized trials | Original research article | 6 | 43 |
| 17 | Ancion A | Serum albumin level and hospital mortality in acute non‐ischemic heart failure | Original research articles | 6 | 44 |
| 17 | Cohen‐Solal A | Beta blocker dose and markers of sympathetic activation in heart failure patients: interrelationships and prognostic significance | Original research article | 6 | 45 |
| 17 | Salem K | Gender‐adjusted and age‐adjusted economic inpatient burden of congestive heart failure: cost and disability‐adjusted life‐year analysis | Original research article | 6 | 46 |
| 17 | Jain A | The renal–cardiac connection in subjects with preserved ejection fraction: a population based study | Original research article | 6 | 47 |
| 17 | Lancellotti P | Protocol update and preliminary results of EACVI/HFA Cardiac Oncology Toxicity (COT) Registry of the European Society of Cardiology | ESC and HFA paper | 6 | 48 |
| 17 | Peled Y | The impact of gender mismatching on early and late outcomes following heart transplantation | Original research article | 6 | 49 |
| 17 | Koyama S | Dynamic changes of serum microRNA‐122‐5p through therapeutic courses indicates amelioration of acute liver injury accompanied by acute cardiac decompensation | Original research article | 6 | 50 |
Top 25 of best cited articles published 2018 in ESC Heart Failure
| Nr. | First author | Title | Type | Times cited | Reference |
|---|
| 1 | Seropian IM | Neutrophil‐to‐lymphocyte ratio and platelet‐to‐lymphocyte ratio as predictors of survival after heart transplantation | Original research article | 8 | 51 |
| 2 | Öhman J | Focused echocardiography and lung ultrasound protocol for guiding treatment in acute heart failure | Original research article | 7 | 52 |
| 2 | Pascual‐Figal D | Rationale and design of TRANSITION: a randomized trial of pre‐discharge vs. post‐discharge initiation of sacubitril/valsartan | Original research article | 7 | 53 |
| 4 | Porto CM | Association between vitamin D deficiency and heart failure risk in the elderly | Original research article | 6 | 54 |
| 4 | Ferreira JP | Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis | Original research article | 6 | 55 |
| 4 | Mustroph J | Empagliflozin reduces Ca/calmodulin‐dependent kinase II activity in isolated ventricular cardiomyocytes | Short communication | 6 | 56 |
| 4 | Smedema JP | Right ventricular involvement and the extent of left ventricular enhancement with magnetic resonance predict adverse outcome in pulmonary sarcoidosis | Original research article | 6 | 57 |
| 4 | Yoshihisa A | Liver fibrosis score predicts mortality in heart failure patients with preserved ejection fraction | Original research article | 6 | 58 |
| 9 | DiCarlo LA | Autonomic regulation therapy to enhance myocardial function in heart failure patients: the ANTHEM‐HFpEF study | Study design | 5 | 59 |
| 9 | Tadmouri A | Cost‐effectiveness of left ventricular assist devices for patients with end‐stage heart failure: analysis of the French hospital discharge database | Original research article | 5 | 60 |
| 9 | Willner N | Semaphorin 4D levels in heart failure patients: a potential novel biomarker of acute heart failure? | Original research article | 5 | 61 |
| 9 | Martens P | Insights into implementation of sacubitril/valsartan into clinical practice | Original research article | 5 | 62 |
| 9 | Shirakabe A | Worsening renal function definition is insufficient for evaluating acute renal failure in acute heart failure | Original research article | 5 | 63 |
| 9 | Lauritsen J | Characteristics and long‐term prognosis of patients with heart failure and mid‐range ejection fraction compared with reduced and preserved ejection fraction: a systematic review and meta‐analysis | Original research article | 5 | 64 |
| 9 | Buckley LF | Low NT‐proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction | Short communication | 5 | 65 |
| 16 | Keene D | Rationale and design of the randomized multicentre His Optimized Pacing Evaluated for Heart Failure (HOPE‐HF) trial | Study design | 4 | 66 |
| 16 | Norberg H | Eligibility of sacubitril‐valsartan in a real‐world heart failure population: a community‐based single‐centre study | Original research article | 4 | 67 |
| 16 | Pitt B | Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease | Original research article | 4 | 68 |
| 16 | Pappalardo F | Full percutaneous biventricular support with two Impella pumps: the Bi‐Pella approach | Case report | 4 | 69 |
| 16 | Lavall D | Mitral valve interventions in heart failure | Review | 4 | 70 |
| 16 | Cattadori G | Exercise and heart failure: an update | Review | 4 | 71 |
| 16 | Bocchi EA | Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial | Original research article | 4 | 72 |
| 23 | Muehlberg F | Native myocardial T1 time can predict development of subsequent anthracycline‐induced cardiomyopathy | Original research article | 3 | 73 |
| 23 | Okabe T | The association between high‐dose loop diuretic use at discharge and cardiovascular mortality in patients with heart failure | Original research article | 3 | 74 |
| 23 | Levinsson A | Sex, drugs, and heart failure: a sex‐sensitive review of the evidence base behind current heart failure clinical guidelines | Review | 3 | 75 |
In order to estimate how the impact factor of ESC‐HF might develop, we compared it to the European Journal of Heart Failure (EJHF, 2018 impact factor 12.129) and European Journal of Preventive Cardiology (EJPC, 2018 impact factor 5.640). Both journals also belong to the ESC Journal Family and have continuously increased their impact factor over the last years (Figure). We expect that ESC‐HF will equally increase its impact factor over the next years. Looking at the most cited articles of EJHF in the past 3 years, one can see that there is a very broad mix of papers that are of increased relevance to the scientific community: ESC guidelines, HFA practice guidelines, HFA position papers, trial designs, original, and review articles (Tables).[[77]] In EJPC, the most cited articles in the past 3 years were predominatly original and review articles (Tables).[[152]] In total, ESC‐HF has published 467 articles so far, EJHF 3717 articles and EJPC 2726 articles.
Top 25 of best cited articles published 2016 in the European Journal of Heart Failure
| Nr. | First author | Title | Type | Times Cited | Reference |
|---|
| 1 | Ponikowski P | 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC | ESC guidelines | 624 | 77 |
| 2 | Lyon AR | Current state of knowledge on Takotsubo syndrome: a position statement from the Task Force on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology | Review | 248 | 78 |
| 3 | Crespo‐Leiro MG | European Society of Cardiology Heart Failure Long‐Term Registry (ESC‐HF‐LT): 1‐year follow‐up outcomes and differences across regions | Research article | 112 | 79 |
| 4 | Harjola V | Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology | Statement | 98 | 80 |
| 5 | van Riet EE | Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review | Research article | 93 | 81 |
| 6 | ter Maaten JM | Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation | Review | 77 | 82 |
| 7 | Jankowska EA | Effects of intravenous iron therapy in iron‐deficient patients with systolic heart failure: a meta‐analysis of randomized controlled trials | Review | 74 | 83 |
| 8 | Vegter EL | MicroRNAs in heart failure: from biomarker to target for therapy | Review | 73 | 84 |
| 9 | Vidán MT | Prevalence and prognostic impact of frailty and its components in non‐dependent elderly patients with heart failure | Research article | 63 | 85 |
| 10 | Stiermaier T | Long‐term excess mortality in takotsubo cardiomyopathy: predictors, causes and clinical consequences | Research article | 60 | 86 |
| 10 | Triposkiadis F | Reframing the association and significance of co‐morbidities in heart failure | Review | 60 | 87 |
| 12 | Ovchinnikova ES | Signature of circulating microRNAs in patients with acute heart failure | Research article | 57 | 88 |
| 13 | Vardeny O | Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM‐HF trial | Research article | 51 | 89 |
| 14 | Schmidt M | Thirty‐year trends in heart failure hospitalization and mortality rates and the prognostic impact of co‐morbidity: a Danish nationwide cohort study | Research article | 49 | 90 |
| 15 | Senni M | Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double‐blind, randomized comparison of two uptitration regimens | Research article | 48 | 91 |
| 16 | Thorvaldsen T | Use of evidence‐based therapy and survival in heart failure in Sweden 2003–2012 | Research article | 46 | 92 |
| 16 | Christ M | Heart failure epidemiology 2000–2013: insights from the German Federal Health Monitoring System | Research article | 46 | 93 |
| 18 | Unger ED | Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction | Research article | 45 | 94 |
| 19 | Aschauer S | The right heart in heart failure with preserved ejection fraction: insights from cardiac magnetic resonance imaging and invasive haemodynamics | Research article | 43 | 95 |
| 20 | Komajda M | Physicians' adherence to guideline‐recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey | Research article | 41 | 96 |
| 20 | Bauersachs J | Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy | HFA practical guidance | 41 | 97 |
| 22 | Demissei BG | Optimizing clinical use of biomarkers in high‐risk acute heart failure patients | Research article | 40 | 98 |
| 23 | Maggioni AP | The real‐world evidence of heart failure: findings from 41 413 patients of the ARNO database | Research article | 39 | 99 |
| 24 | Mann DL | One‐year follow‐up results from AUGMENT‐HF: a multicentre randomized controlled clinical trial of the efficacy of left ventricular augmentation with Algisyl in the treatment of heart failure | Research article | 37 | 100 |
| 24 | Pearse SG | Sleep‐disordered breathing in heart failure | Review | 37 | 101 |
Top 25 of best cited articles published 2017 in the European Journal of Heart Failure
| Nr. | First author | Title | Type | Times cited | Reference |
|---|
| 1 | Jorsal A | Effect of liraglutide, a glucagon‐like peptide‐1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE) – a multicentre, double‐blind, randomised, placebo‐controlled trial | Research article | 72 | 102 |
| 2 | Chioncel O | Epidemiology and one‐year outcomes in patients with chronic heart failure and preserved, mid‐range and reduced ejection fraction: an analysis of the ESC Heart Failure Long‐Term Registry | Research article | 66 | 103 |
| 3 | Pappalardo F | Concomitant implantation of Impella® on top of veno‐arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock | Research article | 63 | 104 |
| 4 | Komajda M | Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo‐controlled trial | Research article | 62 | 105 |
| 5 | Gyöngyösi M | Myocardial fibrosis: biomedical research from bench to bedside | Review | 53 | 106 |
| 6 | Zamorano JL | 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) | ESC position paper | 49 | 107 |
| 7 | Teerlink JR | Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX‐AHF‐2 study | Trial design | 48 | 108 |
| 8 | Tsuji K | Characterization of heart failure patients with mid‐range left ventricular ejection fraction – a report from the CHART‐2 study | Research article | 47 | 109 |
| 9 | Gustafsson F | Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes | Review | 44 | 110 |
| 10 | Butler J | The potential role and rationale for treatment of heart failure with sodium–glucose co‐transporter 2 inhibitors | Review | 38 | 111 |
| 11 | Targher G | In‐hospital and 1‐year mortality associated with diabetes in patients with acute heart failure: results from the ESC‐HFA Heart Failure Long‐Term Registry | Research article | 37 | 112 |
| 11 | Fitchett DH | Heart failure outcomes in clinical trials of glucose‐lowering agents in patients with diabetes | Review | 37 | 113 |
| 13 | Chioncel O | Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long‐Term Registry | Research article | 35 | 114 |
| 14 | Sliwa K | Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM) | Research article | 34 | 115 |
| 14 | Ghio S | Different correlates but similar prognostic implications for right ventricular dysfunction in heart failure patients with reduced or preserved ejection fraction | Research article | 34 | 116 |
| 16 | Löfman I | Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid‐range, and reduced ejection fraction | Research article | 33 | 117 |
| 17 | Meani P | Modalities and effects of left ventricle unloading on extracorporeal life support: a review of the current literature | Supplement article | 32 | 118 |
| 17 | Boriani G | Effects of remote monitoring on clinical outcomes and use of healthcare resources in heart failure patients with biventricular defibrillators: results of the MORE‐CARE multicentre randomized controlled trial | Research article | 32 | 119 |
| 17 | Arrigo M | Precipitating factors and 90‐day outcome of acute heart failure: a report from the intercontinental GREAT registry | Research article | 32 | 120 |
| 17 | Meijers WC | Variability of biomarkers in patients with chronic heart failure and healthy controls | Research article | 32 | 121 |
| 17 | Jansweijer JA | Truncating titin mutations are associated with a mild and treatable form of dilated cardiomyopathy | Research article | 32 | 122 |
| 22 | Devaux Y | Circular RNAs in heart failure | Review | 30 | 123 |
| 23 | Niewinski P | Carotid body resection for sympathetic modulation in systolic heart failure: results from first‐in‐man study | Research article | 29 | 124 |
| 24 | Harjola V | Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) | Review | 28 | 125 |
| 24 | Cannon JA | Dementia‐related adverse events in PARADIGM‐HF and other trials in heart failure with reduced ejection fraction | Research article | 28 | 126 |
Top 25 of best cited articles published 2018 in the European Journal of Heart Failure
| Nr. | First author | Title | Type | Times cited | Reference |
|---|
| 1 | Seferović PM | Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology | HFA position statement | 35 | 127 |
| 2 | Anker SD | Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron‐deficient heart failure patients: an individual patient data meta‐analysis | Research article | 31 | 128 |
| 3 | Lund LH | Heart failure with mid‐range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum | Research article | 28 | 129 |
| 4 | Palazzini M | Pulmonary hypertension due to left heart disease: analysis of survival according to the haemodynamic classification of the 2015 ESC/ERS guidelines and insights for future changes | Research article | 24 | 130 |
| 5 | Hoes MF | Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function | Research article | 18 | 131 |
| 5 | Gorter TM | Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology | HFA position paper | 18 | 132 |
| 7 | Merlo M | Evolving concepts in dilated cardiomyopathy | Review | 17 | 133 |
| 8 | Agostoni P | Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a long‐term comparison | Research article | 16 | 134 |
| 9 | Doehner W | Heart and brain interaction in patients with heart failure: overview and proposal for a taxonomy. A position paper from the Study Group on Heart and Brain Interaction of the Heart Failure Association | HFA position paper | 15 | 135 |
| 10 | Canepa M | Characteristics, treatments and 1‐year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long‐Term Registry | Research article | 14 | 136 |
| 10 | Van Aelst LN | Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion | Research article | 14 | 137 |
| 12 | Geis NA | Safety and efficacy of MitraClip™ therapy in patients with severely impaired left ventricular ejection fraction: results from the German transcatheter mitral valve interventions (TRAMI) registry | Research article | 13 | 138 |
| 13 | Wolsk E | Contribution of cardiac and extra‐cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure | Research article | 12 | 139 |
| 14 | Gupta A | The Hospital Readmissions Reduction Program – learning from failure of a healthcare policy | Review | 11 | 140 |
| 15 | Crespo‐Leiro MG | Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology | HFA position statement | 10 | 141 |
| 15 | Corrà, U | Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology | HFA position paper | 10 | 142 |
| 15 | Ameri P | Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge | Review | 10 | 143 |
| 15 | Cosmi F | Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes | Research article | 10 | 144 |
| 15 | van Boven N | Serially measured circulating microRNAs and adverse clinical outcomes in patients with acute heart failure | Research article | 10 | 145 |
| 15 | Gayat E | Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity‐score matched study | Research article | 10 | 146 |
| 15 | Bayés‐Genis A | Prognostic value of circulating microRNAs on heart failure‐related morbidity and mortality in two large diverse cohorts of general heart failure patients | Research article | 10 | 147 |
| 21 | Sokoreli I | Prognostic value of psychosocial factors for first and recurrent hospitalizations and mortality in heart failure patients: insights from the OPERA‐HF study | Research article | 9 | 148 |
| 21 | Stenemo M | Circulating proteins as predictors of incident heart failure in the elderly | Research article | 9 | 149 |
| 21 | Masson S | Circulating microRNA‐132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure | Research article | 9 | 150 |
| 21 | Dickstein K | CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients – who is doing what to whom and how? | Research article | 9 | 151 |
Top 25 of best cited articles published 2016 in the European Journal of Preventive Cardiology
| Nr. | First author | Title | Type | Times cited | Reference |
|---|
| 1 | Kotseva K | EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries | Research article | 337 | 152 |
| 2 | Piepoli MF | 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) | Research article | 260 | 153 |
| 3 | Eckel N | Metabolically healthy obesity and cardiovascular events: a systematic review and meta‐analysis | Research article | 67 | 154 |
| 4 | Kotseva K | Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross‐sectional survey in 14 European regions | Research article | 65 | 155 |
| 5 | Friis‐Møller N | An updated prediction model of the global risk of cardiovascular disease in HIV‐positive persons: the Data‐collection on Adverse Effects of Anti‐HIV Drugs (D:A:D) study | Research article | 62 | 156 |
| 6 | Rauch B | The prognostic effect of cardiac rehabilitation in the era of acute revascularisation and statin therapy: a systematic review and meta‐analysis of randomized and non‐randomized studies – The Cardiac Rehabilitation Outcome Study (CROS) | Review | 60 | 157 |
| 7 | Price KJ | A review of guidelines for cardiac rehabilitation exercise programmes: is there an international consensus? | Review | 55 | 158 |
| 8 | Bonaccio M | Adherence to the traditional Mediterranean diet and mortality in subjects with diabetes. Prospective results from the MOLI‐SANI study | Research article | 44 | 159 |
| 9 | Roeters van Lennep JE | Cardiovascular disease risk in women with premature ovarian insufficiency: a systematic review and meta‐analysis | Research article | 40 | 160 |
| 10 | Chu P | The effectiveness of yoga in modifying risk factors for cardiovascular disease and metabolic syndrome: a systematic review and meta‐analysis of randomized controlled trials | Research article | 37 | 161 |
| 10 | Cooney MT | Cardiovascular risk estimation in older persons: SCORE OP | Research article | 37 | 162 |
| 12 | Alharbi M | Validation of Fitbit‐Flex as a measure of free‐living physical activity in a community‐based phase III cardiac rehabilitation population | Research article | 34 | 163 |
| 12 | Piepoli MF | Challenges in secondary prevention after acute myocardial infarction: a call for action | Research article | 34 | 164 |
| 14 | D'Ascenzi F | Novel echocardiographic techniques for the evaluation of athletes' heart: a focus on speckle‐tracking echocardiography | Review | 33 | 165 |
| 15 | Fukuta H | Effects of drug and exercise intervention on functional capacity and quality of life in heart failure with preserved ejection fraction: a meta‐analysis of randomized controlled trials | Research article | 32 | 166 |
| 15 | Frederix I | Effect of comprehensive cardiac telerehabilitation on one‐year cardiovascular rehospitalization rate, medical costs and quality of life: a cost‐effectiveness analysis | Research article | 32 | 167 |
| 17 | Hobbs FR | European Primary Care Cardiovascular Society (EPCCS) consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary care | Research article | 31 | 168 |
| 17 | Pallisgaard JL | Risk of atrial fibrillation in diabetes mellitus: a nationwide cohort study | Research article | 31 | 169 |
| 19 | Solberg E | Sudden cardiac arrest in sports – need for uniform registration: a position paper from the Sport Cardiology Section of the European Association for Cardiovascular Prevention and Rehabilitation | Research article | 29 | 170 |
| 20 | Hall AJ | Association between osteoarthritis and cardiovascular disease: systematic review and meta‐analysis | Review | 28 | 171 |
| 20 | Bohm P | Data from a nationwide registry on sports‐related sudden cardiac deaths in Germany | Research article | 28 | 172 |
| 20 | Groenewegen K | Vascular age to determine cardiovascular disease risk: a systematic review of its concepts, definitions, and clinical applications | Research article | 28 | 173 |
| 23 | Taggar JS | Accuracy of methods for detecting an irregular pulse and suspected atrial fibrillation: a systematic review and meta‐analysis | Review | 27 | 174 |
| 23 | Pfaeffli Dale L | The effectiveness of mobile‐health behaviour change interventions for cardiovascular disease self‐management: a systematic review | Review | 27 | 175 |
| 25 | Heida KY | Cardiovascular risk management after reproductive and pregnancy‐related disorders: a Dutch multidisciplinary evidence‐based guideline | Review | 26 | 176 |
Top 25 of best cited articles published 2017 in the European Journal of Preventive Cardiology
| Nr. | First author | Title | Type | Times cited | Reference |
|---|
| 1 | Vigorito C | Frailty and cardiac rehabilitation: a call to action from the EAPC Cardiac Rehabilitation Section | Research article | 39 | 177 |
| 1 | Mont L | Pre‐participation cardiovascular evaluation for athletic participants to prevent sudden death: position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE | Research article | 39 | 178 |
| 3 | Hansen D | The European Association of Preventive Cardiology Exercise Prescription in Everyday Practice and Rehabilitative Training (EXPERT) tool: a digital training and decision support system for optimized exercise prescription in cardiovascular disease. Concept, definitions and construction methodology | Research article | 35 | 179 |
| 4 | Sato T | Cardiopulmonary exercise testing as prognostic indicators: comparisons among heart failure patients with reduced, mid‐range and preserved ejection fraction | Research article | 29 | 180 |
| 5 | Kraal JJ | Clinical and cost‐effectiveness of home‐based cardiac rehabilitation compared to conventional, centre‐based cardiac rehabilitation: results of the FIT@Home study | Research article | 28 | 181 |
| 6 | Pedersen SS | Psychosocial perspectives in cardiovascular disease | Research article | 27 | 182 |
| 7 | Frederix I | Cardiac telerehabilitation: a novel cost‐efficient care delivery strategy that can induce long‐term health benefits | Research article | 26 | 183 |
| 8 | Gorenek B | European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS) | Research article | 25 | 184 |
| 9 | Pogosova N | Psychosocial risk factors in relation to other cardiovascular risk factors in coronary heart disease: results from the EUROASPIRE IV survey. A registry from the European Society of Cardiology | Research article | 23 | 185 |
| 10 | Coppetti T | Accuracy of smartphone apps for heart rate measurement | Research article | 22 | 186 |
| 11 | Ruddox V | Atrial fibrillation and the risk for myocardial infarction, all‐cause mortality and heart failure: a systematic review and meta‐analysis | Review | 21 | 187 |
| 11 | Ribeiro GS | Cardiac rehabilitation programme after transcatheter aortic valve implantation versus surgical aortic valve replacement: systematic review and meta‐analysis | Review | 21 | 188 |
| 13 | Maiorino MI | Effect of a Mediterranean diet on endothelial progenitor cells and carotid intima‐media thickness in type 2 diabetes: follow‐up of a randomized trial | Research article | 19 | 189 |
| 14 | Eichler S | Multicomponent cardiac rehabilitation in patients after transcatheter aortic valve implantation: Predictors of functional and psychocognitive recovery | Research article | 18 | 190 |
| 14 | Pećin I | Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: the role of PCSK9 inhibitors | Review | 18 | 191 |
| 16 | Schiele F | Coronary artery disease: risk stratification and patient selection for more aggressive secondary prevention | Research article | 17 | 192 |
| 16 | Claes J | Longer‐term effects of home‐based exercise interventions on exercise capacity and physical activity in coronary artery disease patients: a systematic review and meta‐analysis | Review | 17 | 193 |
| 16 | Aaby A | Health literacy is associated with health behaviour and self‐reported health: a large population‐based study in individuals with cardiovascular disease | Research article | 17 | 194 |
| 16 | Huang W | Invasive cardiopulmonary exercise testing in the evaluation of unexplained dyspnea: insights from a multidisciplinary dyspnea center | Research article | 17 | 195 |
| 16 | Mundal L | Cardiovascular disease mortality in patients with genetically verified familial hypercholesterolemia in Norway during 1992–2013 | Research article | 17 | 196 |
| 21 | Koolhaas CM | Impact of physical activity on the association of overweight and obesity with cardiovascular disease: the Rotterdam Study | Research article | 16 | 197 |
| 22 | Eyles H | A salt‐reduction smartphone app supports lower‐salt food purchases for people with cardiovascular disease: findings from the SaltSwitch randomised controlled trial | Research article | 15 | 198 |
| 22 | He Q | The association between insomnia symptoms and risk of cardio‐cerebral vascular events: a meta‐analysis of prospective cohort studies | Research article | 15 | 199 |
| 22 | Gomes‐Neto M | High‐intensity interval training versus moderate‐intensity continuous training on exercise capacity and quality of life in patients with coronary artery disease: a systematic review and meta‐analysis | Review | 15 | 200 |
| 25 | Vasankari V | Association of objectively measured sedentary behaviour and physical activity with cardiovascular disease risk | Research article | 14 | 201 |
Top 25 of best cited articles published 2018 in the European Journal of Preventive Cardiology
| Nr. | First author | Title | Type | Times cited | Reference |
|---|
| 1 | Kotseva K | Determinants of participation and risk factor control according to attendance in cardiac rehabilitation programmes in coronary patients in Europe: EUROASPIRE IV survey | Research article | 22 | 202 |
| 2 | Coorey GM | Effectiveness, acceptability and usefulness of mobile applications for cardiovascular disease self‐management: systematic review with meta‐synthesis of quantitative and qualitative data | Review | 18 | 203 |
| 3 | Lee E | Sauna exposure leads to improved arterial compliance: findings from a non‐randomised experimental study | Research article | 16 | 204 |
| 4 | Jørgensen ME | Characteristics and prognosis of heart failure with improved compared with persistently reduced ejection fraction: a systematic review and meta‐analyses | Research article | 13 | 205 |
| 4 | Mancusi C | Higher pulse pressure and risk for cardiovascular events in patients with essential hypertension: the Campania Salute Network | Research article | 13 | 206 |
| 6 | Marmelo F | The impact of prehabilitation on post‐surgical complications in patients undergoing non‐urgent cardiovascular surgical intervention: systematic review and meta‐analysis | Review | 12 | 207 |
| 7 | Tuñón J | Interplay between hypercholesterolaemia and inflammation in atherosclerosis: translating experimental targets into clinical practice | Research article | 11 | 208 |
| 7 | Richards SH | Psychological interventions for coronary heart disease: Cochrane systematic review and meta‐analysis | Review | 11 | 209 |
| 9 | Aune D | Tobacco smoking and the risk of atrial fibrillation: a systematic review and meta‐analysis of prospective studies | Review | 10 | 210 |
| 9 | Munkhaugen J | The prevalence and predictors of elevated C‐reactive protein after a coronary heart disease event | Research article | 10 | 211 |
| 9 | Danchin N | Achievement of low‐density lipoprotein cholesterol goals in 18 countries outside Western Europe: the International ChoLesterol management Practice Study (ICLPS) | Research article | 10 | 212 |
| 9 | Hagger MS | Health literacy in familial hypercholesterolemia: a cross‐national study | Research article | 10 | 213 |
| 9 | Usman MS | Sodium–glucose co‐transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta‐analysis | Research article | 10 | 214 |
| 9 | Lachman S | Impact of physical activity on the risk of cardiovascular disease in middle‐aged and older adults: EPIC Norfolk prospective population study | Research article | 10 | 215 |
| 15 | de Waard AKM | Barriers and facilitators to participation in a health check for cardiometabolic diseases in primary care: a systematic review | Review | 9 | 216 |
| 15 | Häcker AL | Increased arterial stiffness in children with congenital heart disease | Research article | 9 | 217 |
| 17 | Eindhoven DC | Age and gender differences in medical adherence after myocardial infarction: women do not receive optimal treatment – The Netherlands claims database | Research article | 8 | 218 |
| 17 | Hansen D | Do clinicians prescribe exercise similarly in patients with different cardiovascular diseases? Findings from the EAPC EXPERT working group survey | Research article | 8 | 219 |
| 17 | Vidale S | Ambient air pollution and cardiovascular diseases: from bench to bedside | Review | 8 | 220 |
| 17 | Gorostegi‐Anduaga I | Effects of different aerobic exercise programmes with nutritional intervention in sedentary adults with overweight/obesity and hypertension: EXERDIET‐HTA study | Research article | 8 | 221 |
| 21 | Zenti MG | From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: impact on low‐density lipoprotein cholesterol and C‐reactive protein levels in cardiovascular disease patients | Research article | 7 | 222 |
| 21 | Baert A | Factors associated with health‐related quality of life in stable ambulatory congestive heart failure patients: systematic review | Review | 7 | 223 |
| 21 | Morseth B | The ambiguity of physical activity, exercise and atrial fibrillation | Review | 7 | 224 |
| 21 | Doletsky A | Interval training early after heart failure decompensation is safe and improves exercise tolerance and quality of life in selected patients | Research article | 7 | 225 |
| 21 | Schwarz V | Marathon running increases circulating endothelial‐ and thrombocyte‐derived microparticles | Research article | 7 | 226 |
To further look into the best papers ever published in the three different journals, we compared the top 10 ever published papers of all three journals (Tables).[[1], [26], [77], [152], [227]] The average number of citations of the top 10 cited papes in ESC‐HF is 36.1, in EJHF 214.6, and in EJPC 167.7. The best paper so far in ESC‐HF received 143 citations,[226] in EJHF 624,[75] and in EJPC 342.[79] Therefore, one can see that all three journals are on a great path that will lead to further success.
Top 10 of best cited articles published all years in ESC Heart Failure
| Nr. | First author | Title | Type | Year | Times cited | Reference |
|---|
| 1 | Ponikowski P | Heart failure: preventing disease and death worldwide | ESC and HFA paper | 2014 | 143 | 227 |
| 2 | Cowie MR | Improving care for patients with acute heart failure: before, during and after hospitalization | Original research article | 2014 | 53 | 228 |
| 3 | Jujo K | Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure | Original research article | 2016 | 29 | 1 |
| 4 | Konishi M | Heart failure epidemiology and novel treatments in Japan: facts and numbers | Editorial | 2016 | 23 | 2 |
| 4 | Lam CS | Heart failure in southeast Asia: facts and numbers | Editorial | 2015 | 23 | 229 |
| 6 | Springer J | Muscle wasting and sarcopenia in heart failure and beyond: update 2017 | Review | 2017 | 21 | 26 |
| 7 | Ponikowski P | Rationale and design of the CONFIRM‐HF study: a double‐blind, randomized, placebo‐controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency | Original research article | 2014 | 20 | 230 |
| 8 | Haghikia A | Prognostic implication of right ventricular involvement in peripartum cardiomyopathy: a cardiovascular magnetic resonance study | Original research article | 2015 | 17 | 231 |
| 9 | Luedde M | Heart failure is associated with depletion of core intestinal microbiota | Original research article | 2017 | 16 | 27 |
| 9 | Nagarajan V | Obesity paradox in heart failure: a heavy matter | Review | 2016 | 16 | 3 |
Top 10 of best cited articles published all years in the European Journal of Heart Failure
| Nr. | First author | Title | Type | Year | Times cited | Reference |
|---|
| 1 | Ponikowski P | 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC | ESC guidelines | 2016 | 624 | 77 |
| 2 | Maggioni AP | Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long‐Term Registry | Treatment | 2013 | 251 | 232 |
| 3 | Lyon AR | Current state of knowledge on Takotsubo syndrome: a position statement from the Task Force on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology | Review | 2016 | 248 | 78 |
| 4 | Maggioni AP | EURObservational Research Programme: regional differences and 1‐year follow‐up results of the Heart Failure Pilot Survey (ESC‐HF Pilot) | Survey | 2013 | 242 | 233 |
| 5 | Mebazaa A | Recommendations on pre‐hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine | Review | 2015 | 152 | 234 |
| 6 | McMurray JJ | Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin‐converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF) | Study design | 2013 | 150 | 235 |
| 7 | van Deursen VM | Co‐morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey | Co‐morbidities | 2014 | 133 | 236 |
| 8 | Zarrinkoub R | The epidemiology of heart failure, based on data for 2.1 million inhabitants in Sweden | Epidemiology | 2013 | 117 | 237 |
| 8 | Abudiab MM | Cardiac output response to exercise in relation to metabolic demand in heart failure with preserved ejection fraction | Exercise physiology | 2013 | 117 | 238 |
| 10 | Crespo‐Leiro MG | European Society of Cardiology Heart Failure Long‐Term Registry (ESC‐HF‐LT): 1‐year follow‐up outcomes and differences across regions | Research article | 2016 | 112 | 79 |
Top 10 of best cited articles published all years in the European Journal of Preventive Cardiology
| Nr. | First Author | Title | Type | Year | Times Cited | Reference |
|---|
| 1 | Kotseva K | EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries | Research article | 2016 | 342 | 152 |
| 2 | Piepoli MF | 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) | Research article | 2016 | 264 | 153 |
| 3 | Piepoli MF | Secondary prevention in the clinical management of patients with cardiovascular diseases. Core components, standards and outcome measures for referral and delivery: a Policy Statement from the Cardiac Rehabilitation Section of the European Association for Cardiovascular Prevention & Rehabilitation. Endorsed by the Committee for Practice Guidelines of the European Society of Cardiology | Research article | 2014 | 189 | 239 |
| 4 | Perk J | European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) | Research article | 2012 | 155 | 240 |
| 5 | Sofi F | Insomnia and risk of cardiovascular disease: a meta‐analysis | Research article | 2014 | 142 | 241 |
| 6 | Molmen‐Hansen HE | Aerobic interval training reduces blood pressure and improves myocardial function in hypertensive patients | Research article | 2012 | 134 | 242 |
| 7 | Vanhees L | Importance of characteristics and modalities of physical activity and exercise in defining the benefits to cardiovascular health within the general population: recommendations from the EACPR (Part I) | Review | 2012 | 132 | 243 |
| 8 | Mezzani A | Aerobic exercise intensity assessment and prescription in cardiac rehabilitation: a joint position statement of the European Association for Cardiovascular Prevention and Rehabilitation, the American Association of Cardiovascular and Pulmonary Rehabilitation and the Canadian Association of Cardiac Rehabilitation | Research article | 2013 | 113 | 244 |
| 9 | Neubeck L | Participating in cardiac rehabilitation: a systematic review and meta‐synthesis of qualitative data | Review | 2012 | 108 | 245 |
| 10 | Finegold JA | What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo‐controlled trials to aid individual patient choice | Research article | 2014 | 98 | 246 |
Conflict of interest: none declared.
[
References
1
Jujo K, Saito K, Ishida I, Furuki Y, Kim A, Suzuki Y, Sekiguchi H, Yamaguchi J, Ogawa H, Hagiwara N. Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure. ESC Heart Fail 2016 ; 3 : 177 – 188.
2
Konishi M, Ishida J, Springer J, Haehling S, Akashi YJ, Shimokawa H, Anker SD. Heart failure epidemiology and novel treatments in Japan: facts and numbers. ESC Heart Fail 2016 ; 3 : 145 – 151.
3
Nagarajan V, Kohan L, Holland E, Keeley EC, Mazimba S. Obesity paradox in heart failure: a heavy matter. ESC Heart Fail 2016 ; 3 : 227 – 234.
4
Arrigo M, Tolppanen H, Sadoune M, Feliot E, Teixeira A, Laribi S, Plaisance P, Nouira S, Yilmaz MB, Gayat E, Mebazaa A. Effect of precipitating factors of acute heart failure on readmission and long‐term mortality. ESC Heart Fail 2016 ; 3 : 115 – 121.
5
Núñez J, Monmeneu JV, Mollar A, Núñez E, Bodí V, Miñana G, García‐Blas S, Santas E, Agüero J, Chorro FJ, Sanchis J, López‐Lereu MP. Left ventricular ejection fraction recovery in patients with heart failure treated with intravenous iron: a pilot study. ESC Heart Fail 2016 ; 3 : 293 – 298.
6
Sotiropoulos K, Yerly P, Monney P, Garnier A, Regamey J, Hugli O, Martin D, Metrich M, Antonietti JP, Hullin R. Red cell distribution width and mortality in acute heart failure patients with preserved and reduced ejection fraction. ESC Heart Fail 2016 ; 3 : 198 – 204.
7
Hayashi T, Hasegawa T, Kanzaki H, Funada A, Amaki M, Takahama H, Ohara T, Sugano Y, Yasuda S, Ogawa H, Anzai T. Subclinical hypothyroidism is an independent predictor of adverse cardiovascular outcomes in patients with acute decompensated heart failure. ESC Heart Fail 2016 ; 3 : 168 – 176.
8
Sato A, Yoshihisa A, Kanno Y, Takiguchi M, Miura S, Shimizu T, Nakamura Y, Yamauchi H, Owada T, Sato T, Suzuki S, Oikawa M, Yamaki T, Sugimoto K, Kunii H, Nakazato K, Suzuki H, Saitoh SI, Takeishi Y. Associations of dipeptidyl peptidase‐4 inhibitors with mortality in hospitalized heart failure patients with diabetes mellitus. ESC Heart Fail 2016 ; 3 : 77 – 85.
9
Yoshihisa A, Watanabe S, Kanno Y, Takiguchi M, Sato A, Yokokawa T, Miura S, Shimizu T, Abe S, Sato T, Suzuki S, Oikawa M, Sakamoto N, Yamaki T, Sugimoto K, Kunii H, Nakazato K, Suzuki H, Saitoh S, Takeishi Y. The CHA 2 DS 2 ‐VASc score as a predictor of high mortality in hospitalized heart failure patients. ESC Heart Fail 2016 ; 3 : 261 – 269.
Hoshida S, Shinoda Y, Ikeoka K, Fukuoka H, Inui H, Watanabe T. Age‐ and sex‐related differences in diastolic function and cardiac dimensions in a hypertensive population. ESC Heart Fail 2016 ; 3 : 270 – 277.
Searle J, Frick J, Möckel M. Acute heart failure facts and numbers: acute heart failure populations. ESC Heart Fail 2016 ; 3 : 65 – 70.
Thomsen MM, Lewinter C, Køber L. Varying effects of recommended treatments for heart failure with reduced ejection fraction: meta‐analysis of randomized controlled trials in the ESC and ACCF/AHA guidelines. ESC Heart Fail 2016 ; 3 : 235 – 244.
Savage HO, Khushaba RN, Zaffaroni A, Colefax M, Farrugia S, Schindhelm K, Teschler H, Weinreich G, Grueger H, Neddermann M, Heneghan C, Simonds A, Cowie MR. Development and validation of a novel non‐contact monitor of nocturnal respiration for identifying sleep‐disordered breathing in patients with heart failure. ESC Heart Fail 2016 ; 3 : 212 – 219.
Aleksova N, Demers C, Strachan PH, MacIver J, Downar J, Fowler R, Heyland DK, Ross HJ, You JJ. Barriers to goals of care discussions with hospitalized patients with advanced heart failure: feasibility and performance of a novel questionnaire. ESC Heart Fail 2016 ; 3 : 245 – 252.
Meems LM, Brouwers FP, Joosten MM, Lambers Heerspink HJ, Zeeuw D, Bakker SJ, Gansevoort RT, Gilst WH, Harst P, Boer RA. Plasma calcidiol, calcitriol, and parathyroid hormone and risk of new onset heart failure in a population‐based cohort study. ESC Heart Fail 2016 ; 3 : 189 – 197.
Ahmed MB, Patel K, Fonarow GC, Morgan CJ, Butler J, Bittner V, Kulczycki A, Kheirbek RE, Aronow WS, Fletcher RD, Brown CJ, Ahmed A. Higher risk for incident heart failure and cardiovascular mortality among community‐dwelling octogenarians without pneumococcal vaccination. ESC Heart Fail 2016 ; 3 : 11 – 17.
Yamamoto E, Hirata Y, Tokitsu T, Kusaka H, Tabata N, Tsujita K, Yamamuro M, Kaikita K, Watanabe H, Hokimoto S, Maruyama T, Ogawa H. The clinical significance of plasma neopterin in heart failure with preserved left ventricular ejection fraction. ESC Heart Fail 2016 ; 3 : 53 – 59.
Miller WL, Jaffe AS. Biomarkers in heart failure: the importance of inconvenient details. ESC Heart Fail 2016 ; 3 : 3 – 10.
Yeo TJ, Yeo PS, Hadi FA, Cushway T, Lee KY, Tai BC, Lam CS. Rationale and design of a pilot randomized controlled trial to assess the role of intravenous ferric carboxymaltose in Asian patients with heart failure (PRACTICE‐ASIA‐HF). ESC Heart Fail 2016 ; 3 : 71 – 76.
Olesen LL, Andersen A. ECG as a first step in the detection of left ventricular systolic dysfunction in the elderly. ESC Heart Fail 2016 ; 3 : 44 – 52.
Ntusi NA, Ntsekhe M. Human immunodeficiency virus‐associated heart failure in sub‐Saharan Africa: evolution in the epidemiology, pathophysiology, and clinical manifestations in the antiretroviral era. ESC Heart Fail 2016 ; 3 : 158 – 167.
Kapeller B, Mueller J, Losert U, Podesser BK, Macfelda K. Microcurrent stimulation promotes reverse remodelling in cardiomyocytes. ESC Heart Fail 2016 ; 3 : 122 – 130.
Ortega A, Roselló‐Lletí E, Tarazón E, Gil‐Cayuela C, Lago F, González‐Juanatey JR, Martinez‐Dolz L, Portolés M, Rivera M. TRPM7 is down‐regulated in both left atria and left ventricle of ischaemic cardiomyopathy patients and highly related to changes in ventricular function. ESC Heart Fail 2016 ; 3 : 220 – 224.
Okabe T, Yakushiji T, Hiroe M, Oyama Y, Igawa W, Ono M, Kido T, Ebara S, Yamashita K, Yamamoto MH, Saito S, Hoshimoto K, Kisaki A, Isomura N, Araki H, Ochiai M. Steroid pulse therapy was effective for cardiac sarcoidosis with ventricular tachycardia and systolic dysfunction. ESC Heart Fail 2016 ; 3 : 288 – 292.
Pya Y, Bekbossynova M, Jetybayeva S, Bekbossynov S, Andossova S, Salov R, Medressova A, Novikova S, Murzagaliyev M. Initial 3‐year outcomes with left ventricular assist devices in a country with a nascent heart transplantation program. ESC Heart Fail 2016 ; 3 : 26 – 34.
Springer J, Springer JI, Anker SD. Muscle wasting and sarcopenia in heart failure and beyond: update 2017. ESC Heart Fail 2017 ; 4 : 492 – 498.
Luedde M, Winkler T, Heinsen FA, Rühlemann MC, Spehlmann ME, Bajrovic A, Lieb W, Franke A, Ott SJ, Frey N. Heart failure is associated with depletion of core intestinal microbiota. ESC Heart Fail 2017 ; 4 : 282 – 290.
Riley JP, Beattie JM. Palliative care in heart failure: facts and numbers. ESC Heart Fail 2017 ; 4 : 81 – 87.
Saitoh M, Dos Santos MR, Emami A, Ishida J, Ebner N, Valentova M, Bekfani T, Sandek A, Lainscak M, Doehner W, Anker SD, von Haehling S. Anorexia, functional capacity, and clinical outcome in patients with chronic heart failure: results from the Studies Investigating Co‐morbidities Aggravating Heart Failure (SICA‐HF). ESC Heart Fail 2017 ; 4 : 448 – 457.
Delepaul B, Robin G, Delmas C, Moine T, Blanc A, Fournier P, Roger‐Rollé A, Domain G, Delon C, Uzan C, Boudjellil R, Carrié D, Roncalli J, Galinier M, Lairez O. Who are patients classified within the new terminology of heart failure from the 2016 ESC guidelines? ESC Heart Fail 2017 ; 4 : 99 – 104.
Barkhudaryan A, Scherbakov N, Springer J, Doehner W. Cardiac muscle wasting in individuals with cancer cachexia. ESC Heart Fail 2017 ; 4 : 458 – 467.
Amin A, Chitsazan M, Shiukhi Ahmad Abad F, Taghavi S, Naderi N. On admission serum sodium and uric acid levels predict 30 day rehospitalization or death in patients with acute decompensated heart failure. ESC Heart Fail 2017 ; 4 : 162 – 168.
Morishita T, Uzui H, Mitsuke Y, Amaya N, Kaseno K, Ishida K, Fukuoka Y, Ikeda H, Tama N, Yamazaki T, Lee JD, Tada H. Association between matrix metalloproteinase‐9 and worsening heart failure events in patients with chronic heart failure. ESC Heart Fail 2017 ; 4 : 321 – 330.
Alma LJ, Bokslag A, Maas AH, Franx A, Paulus WJ, de Groot CJM. Shared biomarkers between female diastolic heart failure and pre‐eclampsia: a systematic review and meta‐analysis. ESC Heart Fail 2017 ; 4 : 88 – 98.
Trippel TD, Holzendorf V, Halle M, Gelbrich G, Nolte K, Duvinage A, Schwarz S, Rutscher T, Wiora J, Wachter R, Herrmann‐Lingen C, Duengen HD, Hasenfuß G, Pieske B, Edelmann F. Ghrelin and hormonal markers under exercise training in patients with heart failure with preserved ejection fraction: results from the Ex‐DHF pilot study. ESC Heart Fail 2017 ; 4 : 56 – 65.
Khan MS, Fonarow GC, Khan H, Greene SJ, Anker SD, Gheorghiade M, Butler J. Renin‐angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta‐analysis. ESC Heart Fail 2016 ; 4 : 402 – 408.
Möckel M, Searle J, Maisel A. The role of procalcitonin in acute heart failure patients. ESC Heart Fail 2017 ; 4 : 203 – 208.
Toma M, Mak GJ, Chen V, Hollander Z, Shannon CP, Lam KK, Ng RT, Tebbutt SJ, Wilson‐McManus JE, Ignaszewski A, Anderson T, Dyck JRB, Howlett J, Ezekowitz J, McManus BM, Oudit GY. Differentiating heart failure phenotypes using sex‐specific transcriptomic and proteomic biomarker panels. ESC Heart Fail 2017 ; 4 : 301 – 311.
Yoshihisa A, Watanabe S, Yokokawa T, Misaka T, Sato T, Suzuki S, Oikawa M, Kobayashi A, Takeishi Y. Associations between acylcarnitine to free carnitine ratio and adverse prognosis in heart failure patients with reduced or preserved ejection fraction. ESC Heart Fail 2017 ; 4 : 360 – 364.
Jaarsma T. Sexual function of patients with heart failure: facts and numbers. ESC Heart Fail 2017 ; 4 : 3 – 7.
Theidel U, Väätäinen S, Martikainen J, Soini E, Hardt T, Doehner W. Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany. ESC Heart Fail 2017 ; 4 : 274 – 281.
Pose A, Almenar L, Gavira JJ, López‐Granados A, Blasco T, Delgado J, Aramburu O, Rodríguez A, Manzano L, Manito N. Benefit of tolvaptan in the management of hyponatraemia in patients with diuretic‐refractory congestive heart failure: the SEMI‐SEC project. ESC Heart Fail 2017 ; 4 : 130 – 137.
Silvetti S, Belletti A, Fontana A, Pollesello P. Rehospitalization after intermittent levosimendan treatment in advanced heart failure patients: a meta‐analysis of randomized trials. ESC Heart Fail 2017 ; 4 : 595 – 604.
Ancion A, Allepaerts S, Oury C, Gori AS, Piérard LA, Lancellotti P. Serum albumin level and hospital mortality in acute non‐ischemic heart failure. ESC Heart Fail 2017 ; 4 : 138 – 145.
Cohen‐Solal A, Jacobson AF, Piña IL. Beta blocker dose and markers of sympathetic activation in heart failure patients: interrelationships and prognostic significance. ESC Heart Fail 2017 ; 4 : 499 – 506.
Salem K, ElKhateeb O. Gender‐adjusted and age‐adjusted economic inpatient burden of congestive heart failure: cost and disability‐adjusted life‐year analysis. ESC Heart Fail 2017 ; 4 : 259 – 265.
Jain A, Scott C, Chen HH. The renal‐cardiac connection in subjects with preserved ejection fraction: a population based study. ESC Heart Fail 2017 ; 4 : 266 – 273.
Lancellotti P, Galderisi M, Donal E, Edvardsen T, Popescu BA, Farmakis D, Filippatos G, Habib G, Lestuzzi C, Santoro C, Moonen M, Jerusalem G, Andarala M, Anker SD ; ESC Cardiac Oncology Toxicity Long‐Term Registry Investigators. Protocol update and preliminary results of EACVI/HFA Cardiac Oncology Toxicity (COT) Registry of the European Society of Cardiology. ESC Heart Fail 2017 ; 4 : 312 – 318.
Peled Y, Lavee J, Arad M, Shemesh Y, Katz M, Kassif Y, Asher E, Elian D, Har‐Zahav Y, Goldenberg I, Freimark D. The impact of gender mismatching on early and late outcomes following heart transplantation. ESC Heart Fail 2017 ; 4 : 31 – 39.
Koyama S, Kuragaichi T, Sato Y, Kuwabara Y, Usami S, Horie T, Baba O, Hakuno D, Nakashima Y, Nishino T, Nishiga M, Nakao T, Arai H, Kimura T, Ono K. Dynamic changes of serum microRNA‐122‐5p through therapeutic courses indicates amelioration of acute liver injury accompanied by acute cardiac decompensation. ESC Heart Fail 2017 ; 4 : 112 – 121.
Seropian IM, Romeo FJ, Pizarro R, Vulcano NO, Posatini RA, Marenchino RG, Berrocal DH, Belziti CA. Neutrophil‐to‐lymphocyte ratio and platelet‐to‐lymphocyte ratio as predictors of survival after heart transplantation. ESC Heart Fail 2018 ; 5 : 149 – 156.
Öhman J, Harjola VP, Karjalainen P, Lassus J. Focused echocardiography and lung ultrasound protocol for guiding treatment in acute heart failure. ESC Heart Fail 2018 ; 5 : 120 – 128.
Pascual‐Figal D, Wachter R, Senni M, Belohlavek J, Noè A, Carr D, Butylin D. Rationale and design of TRANSITION: a randomized trial of pre‐discharge vs. post‐discharge initiation of sacubitril/valsartan. ESC Heart Fail 2018 ; 5 : 327 – 336.
Porto CM, Silva VL, da Luz JS, Filho BM, da Silveira VM. Association between vitamin D deficiency and heart failure risk in the elderly. ESC Heart Fail 2018 ; 5 : 63 – 74.
Ferreira JP, Machu JL, Girerd N, Jaisser F, Thum T, Butler J, González A, Diez J, Heymans S, McDonald K, Gyöngyösi M, Firat H, Rossignol P, Pizard A, Zannad F. Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis. ESC Heart Fail 2018 ; 5 : 139 – 148.
Mustroph J, Wagemann O, Lücht CM, Trum M, Hammer KP, Sag CM, Lebek S, Tarnowski D, Reinders J, Perbellini F, Terracciano C, Schmid C, Schopka S, Hilker M, Zausig Y, Pabel S, Sossalla ST, Schweda F, Maier LS, Wagner S. Empagliflozin reduces Ca/calmodulin‐dependent kinase II activity in isolated ventricular cardiomyocytes. ESC Heart Fail 2018 ; 5 : 642 – 648.
Smedema JP, van Geuns RJ, Ector J, Heidbuchel H, Ainslie G, Crijns HJ. Right ventricular involvement and the extent of left ventricular enhancement with magnetic resonance predict adverse outcome in pulmonary sarcoidosis. ESC Heart Fail 2018 ; 5 : 157 – 171.
Yoshihisa A, Sato Y, Yokokawa T, Sato T, Suzuki S, Oikawa M, Kobayashi A, Yamaki T, Kunii H, Nakazato K, Saitoh SI, Takeishi Y. Liver fibrosis score predicts mortality in heart failure patients with preserved ejection fraction. ESC Heart Fail 2018 ; 5 : 262 – 270.
DiCarlo LA, Libbus I, Kumar HU, Mittal S, Premchand RK, Amurthur B, KenKnight BH, Ardell JL, Anand IS. Autonomic regulation therapy to enhance myocardial function in heart failure patients: the ANTHEM‐HFpEF study. ESC Heart Fail 2018 ; 5 : 95 – 100.
Tadmouri A, Blomkvist J, Landais C, Seymour J, Azmoun A. Cost‐effectiveness of left ventricular assist devices for patients with end‐stage heart failure: analysis of the French hospital discharge database. ESC Heart Fail 2018 ; 5 : 75 – 86.
Willner N, Goldberg Y, Schiff E, Vadasz Z. Semaphorin 4D levels in heart failure patients: a potential novel biomarker of acute heart failure? ESC Heart Fail 2018 ; 5 : 603 – 609.
Martens P, Beliën H, Dupont M, Mullens W. Insights into implementation of sacubitril/valsartan into clinical practice. ESC Heart Fail 2018 ; 5 : 275 – 283.
Shirakabe A, Hata N, Kobayashi N, Matsushita M, Shibata Y, Nishigoori S, Uchiyama S, Asai K, Shimizu W. Worsening renal function definition is insufficient for evaluating acute renal failure in acute heart failure. ESC Heart Fail 2018 ; 5 : 322 – 331.
Lauritsen J, Gustafsson F, Abdulla J. Characteristics and long‐term prognosis of patients with heart failure and mid‐range ejection fraction compared with reduced and preserved ejection fraction: a systematic review and meta‐analysis. ESC Heart Fail 2018 ; 5 : 685 – 694.
Buckley LF, Canada JM, Del Buono MG, Carbone S, Trankle CR, Billingsley H, Kadariya D, Arena R, Van Tassell BW, Abbate A. Low NT‐proBNP levels in overweight and obese patients do not rule out a diagnosis of heart failure with preserved ejection fraction. ESC Heart Fail 2018 ; 5 : 372 – 378.
Keene D, Arnold A, Shun‐Shin MJ, Howard JP, Sohaib SA, Moore P, Tanner M, Quereshi N, Muthumala A, Chandresekeran B, Foley P, Leyva F, Adhya S, Falaschetti E, Tsang H, Vijayaraman P, Cleland JG, Stegemann B, Francis DP, Whinnett ZI. Rationale and design of the randomized multicentre His Optimized Pacing Evaluated for Heart Failure (HOPE‐HF) trial. ESC Heart Fail 2018 ; 5 : 965 – 976.
Norberg H, Bergdahl E, Lindmark K. Eligibility of sacubitril‐valsartan in a real‐world heart failure population: a community‐based single‐centre study. ESC Heart Fail 2018 ; 5 : 337 – 343.
Pitt B, Bushinsky DA, Kitzman DW, Ruschitzka F, Metra M, Filippatos G, Rossignol P, Du Mond C, Garza D, Berman L, Lainscak M ; Patiromer‐204 Investigators. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease. ESC Heart Fail 2018 ; 5 : 257 – 266.
Pappalardo F, Scandroglio AM, Latib A. Full percutaneous biventricular support with two Impella pumps: the Bi‐Pella approach. ESC Heart Fail 2018 ; 5 : 368 – 371.
Lavall D, Hagendorff A, Schirmer SH, Böhm M, Borger MA, Laufs U. Mitral valve interventions in heart failure. ESC Heart Fail 2018 ; 5 : 552 – 561.
Cattadori G, Segurini C, Picozzi A, Padeletti L, Anzà C. Exercise and heart failure: an update. ESC Heart Fail 2018 ; 5 : 222 – 232.
Bocchi EA, Rassi S, Guimarães GV ; Argentina, Chile, and Brazil SHIFT Investigators. Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial. ESC Heart Fail 2018 ; 5 : 249 – 256.
Muehlberg F, Funk S, Zange L, von Knobelsdorff‐Brenkenhoff F, Blaszczyk E, Schulz A, Ghani S, Reichardt A, Reichardt P, Schulz‐Menger J. Native myocardial T1 time can predict development of subsequent anthracycline‐induced cardiomyopathy. ESC Heart Fail 2018 ; 5 : 620 – 629.
Okabe T, Yakushiji T, Kido T, Oyama Y, Igawa W, Ono M, Ebara S, Yamashita K, Yamamoto MH, Saito S, Amemiya K, Isomura N, Ochiai M. The association between high‐dose loop diuretic use at discharge and cardiovascular mortality in patients with heart failure. ESC Heart Fail 2018 ; 5 : 87 – 94.
Levinsson A, Dubé MP, Tardif JC, de Denus S. Sex, drugs, and heart failure: a sex‐sensitive review of the evidence base behind current heart failure clinical guidelines. ESC Heart Fail 2018 ; 5 : 745 – 754.
Web of Science –Clarivate Analytics. www.webofknowledge.com
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González‐Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016 ; 18 : 891 – 975.
Lyon AR, Bossone E, Schneider B, Sechtem U, Citro R, Underwood SR, Sheppard MN, Figtree GA, Parodi G, Akashi YJ, Ruschitzka F, Filippatos G, Mebazaa A, Omerovic E. Current state of knowledge on Takotsubo syndrome: a position statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2106 ; 18 : 8 – 27.
Crespo‐Leiro MG, Anker SD, Maggioni AP, Coats AJ, Filippatos G, Ruschitzka F, Ferrari R, Piepoli MF, Delgado Jimenez JF, Metra M, Fonseca C, Hradec J, Amir O, Logeart D, Dahlström U, Merkely B, Drozdz J, Goncalvesova E, Hassanein M, Chioncel O, Lainscak M, Seferovic PM, Tousoulis D, Kavoliuniene A, Fruhwald F, Fazlibegovic E, Temizhan A, Gatzov P, Erglis A, Laroche C, Mebazaa A ; Heart Failure Association (HFA) of the European Society of Cardiology (ESC) European Society of Cardiology Heart Failure Long‐Term Registry (ESC‐HF‐LT): 1‐year follow‐up outcomes and differences across regions. Eur J Heart Fail 2016 ; 18 : 613 – 625.
Harjola V, Mebazaa A, Čelutkienė J, Bettex D, Bueno H, Chioncel O, Crespo‐Leiro MG, Falk V, Filippatos G, Gibbs S, Leite‐Moreira A, Lassus J, Masip J, Mueller C, Mullens W, Naeije R, Nordegraaf AV, Parissis J, Riley JP, Ristic A, Rosano G, Rudiger A, Ruschitzka F, Seferovic P, Sztrymf B, Vieillard‐Baron A, Yilmaz MB, Konstantinides S. Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. Eur J Heart Fail 2016 ; 18 : 226 – 241.
van Riet EE, Hoes AW, Wagenaar KP, Limburg A, Landman MA, Rutten FH. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail 2016 ; 18 : 242 – 252.
ter Maaten JM, Damman K, Verhaar MC, Paulus WJ, Duncker DJ, Cheng C, Heerebeek L, Hillege HL, Lam CS, Navis G, Voors AA. Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation. Eur J Heart Fail 2016 ; 18 : 588 – 598.
Jankowska EA, Tkaczyszyn M, Suchocki T, Drozd M, von Haehling S, Doehner W, Banasiak W, Filippatos G, Anker SD, Ponikowski P. Effects of intravenous iron therapy in iron‐deficient patients with systolic heart failure: a meta‐analysis of randomized controlled trials. Eur J Heart Fail 2016 ; 18 : 786 – 795.
Vegter EL, van der Meer P, de Windt LJ, Pinto YM, Voors AA. MicroRNAs in heart failure: from biomarker to target for therapy. Eur J Heart Fail 2016 ; 18 : 457 – 468.
Vidán MT, Blaya‐Novakova V, Sánchez E, Ortiz J, Serra‐Rexach JA, Bueno H. Prevalence and prognostic impact of frailty and its components in non‐dependent elderly patients with heart failure. Eur J Heart Fail 2016 ; 18 : 869 – 875.
Stiermaier T, Moeller C, Oehler K, Desch S, Graf T, Eitel C, Vonthein R, Schuler G, Thiele H, Eitel I. Long‐term excess mortality in takotsubo cardiomyopathy: predictors, causes and clinical consequences. Eur J Heart Fail 2016 ; 18 : 650 – 656.
Triposkiadis F, Giamouzis G, Parissis J, Starling RC, Boudoulas H, Skoularigis J, Butler J, Filippatos G. Reframing the association and significance of co‐morbidities in heart failure. Eur J Heart Fail 2016 ; 18 : 744 – 758.
Ovchinnikova ES, Schmitter D, Vegter EL, ter Maaten JM, Valente MA, Liu LC, van der Harst P, Pinto YM, de Boer RA, Meyer S, Teerlink JR, O'Connor CM, Metra M, Davison BA, Bloomfield DM, Cotte G, Cleland JG, Mebazaa A, Laribi S, Givertz MM, Ponikowski P, van der Meer P, van Veldhuisen DJ, Voors AA, Berezikov E. Signature of circulating microRNAs in patients with acute heart failure. Eur J Heart Fail 2016 ; 18 : 414 – 423.
Vardeny O, Claggett B, Packer M, Zile MR, Rouleau J, Swedberg K, Teerlink JR, Desai AS, Lefkowitz M, Shi V, JJ MM, Solomon SD ; Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM‐HF) Investigators Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM‐HF trial. Eur J Heart Fail 2016 ; 18 : 1228 – 1234.
Schmidt M, Ulrichsen SP, Pedersen L, Bøtker HE, Sørensen HT. Thirty‐year trends in heart failure hospitalization and mortality rates and the prognostic impact of co‐morbidity: a Danish nationwide cohort study. Eur J Heart Fail 2016 ; 18 : 490 – 499.
Senni M, McMurray JJ, Wachter R, McIntyre HF, Reyes A, Majercak I, Andreka P, Shehova‐Yankova N, Anand I, Yilmaz MB, Gogia H, Martinez‐Selles M, Fischer S, Zilahi Z, Cosmi F, Gelev V, Galve E, Gómez‐Doblas JJ, Nociar J, Radomska M, Sokolova B, Volterrani M, Sarkar A, Reimund B, Chen F, Charney A. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double‐blind, randomized comparison of two uptitration regimens. Eur J Heart Fail 2016 ; 18 : 1193 – 1202.
Thorvaldsen T, Benson L, Dahlström U, Edner M, Lund LH. Use of evidence‐based therapy and survival in heart failure in Sweden 2003–2012. Eur J Heart Fail 2016 ; 18 : 503 – 511.
Christ M, Störk S, Dörr M, Heppner HJ, Müller C, Wachter R, Riemer U. Heart failure epidemiology 2000–2013: insights from the German Federal Health Monitoring System. Eur J Heart Fail 2016 ; 18 : 1009 – 1018.
Unger ED, Dubin RF, Deo R, Daruwalla V, Friedman JL, Medina C, Beussink L, Freed BH, Shah SJ. Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 2016 ; 18 : 103 – 112.
Aschauer S, Kammerlander AA, Zotter‐Tufaro C, Ristl R, Pfaffenberger S, Bachmann A, Duca F, Marzluf BA, Bonderman D, Mascherbauer J. The right heart in heart failure with preserved ejection fraction: insights from cardiac magnetic resonance imaging and invasive haemodynamics. Eur J Heart Fail 2016 ; 18 : 71 – 80.
Komajda M, Anker SD, Cowie MR, Filippatos GS, Mengelle B, Ponikowski P, Tavazzi L. Physicians' adherence to guideline‐recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. Eur J Heart Fail 2016 ; 18 : 514 – 522.
Bauersachs J, Arrigo M, Hilfiker‐Kleiner D, Veltmann C, Coats AJ, Crespo‐Leiro MG, De Boer RA, van der Meer P, Maack C, Mouquet F, Petrie MC, Piepoli MF, Regitz‐Zagrosek V, Schaufelberger M, Seferovic P, Tavazzi L, Ruschitzka F, Mebazaa A, Sliwa K. Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail 2016 ; 18 : 1096 – 1105.
Demissei BG, Valente MA, Cleland JG, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison B, Givertz MM, Bloomfield DM, Dittrich H, van der Meer P, van Veldhuisen DJ, Hillege HL, Voors AA. Optimizing clinical use of biomarkers in high‐risk acute heart failure patients. Eur J Heart Fail 2016 ; 18 : 269 – 280.
Maggioni AP, Orso F, Calabria S, Rossi E, Cinconze E, Baldasseroni S, Martini N. The real‐world evidence of heart failure: findings from 41 413 patients of the ARNO database. Eur J Heart Fail 2016 ; 18 : 402 – 410.
Mann DL, Lee RJ, Coats AJ, Neagoe G, Dragomir D, Pusineri E, Piredda M, Bettari L, Kirwan B, Dowling R, Volterrani M, Solomon SD, Sabbah HN, Hinson A, Anker SD. One‐year follow‐up results from AUGMENT‐HF: a multicentre randomized controlled clinical trial of the efficacy of left ventricular augmentation with Algisyl in the treatment of heart failure. Eur J Heart Fail 2016 ; 18 : 314 – 325.
Pearse SG, Cowie MR. Sleep‐disordered breathing in heart failure. Eur J Heart Fail 2016 ; 18 : 353 – 361.
Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hänselmann A, Nilsson B, Møller JE, Hjort J, Rasmussen J, Boesgaard TW, Schou M, Videbæk L, Gustafsson I, Flyvbjerg A, Wiggers H, Tarnow L. Effect of liraglutide, a glucagon‐like peptide‐1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE) –a multicentre, double‐blind, randomised, placebo‐controlled trial. Eur J Heart Fail 2017 ; 19 : 69 – 77.
Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo‐Leiro MG, Harjola V, Parissis J, Laroche C, Piepoli MF, Fonseca C, Mebazaa A, Lund L, Ambrosio GA, Coats AJ, Ferrari R, Ruschitzka F, Maggioni AP, Filippatos G. Epidemiology and one‐year outcomes in patients with chronic heart failure and preserved, mid‐range and reduced ejection fraction: an analysis of the ESC Heart Fail Long‐Term Registry. Eur J Heart Fail 2017 ; 19 : 1574 – 1585.
Pappalardo F, Schulte C, Pieri M, Schrage B, Contri R, Soeffker G, Greco T, Lembo R, Müllerleile K, Colombo A, Sydow K, De Bonis M, Wagner F, Reichenspurner H, Blankenberg S, Zangrillo A, Westermann D. Concomitant implantation of Impella® on top of veno‐arterial extracorporeal membrane oxygenation may improve survival of patients with cardiogenic shock. Eur J Heart Fail 2017 ; 19 : 404 – 412.
Komajda M, Isnard R, Cohen‐Solal A, Metra M, Pieske B, Ponikowski P, Voors AA, Dominjon F, Henon‐Goburdhun C, Pannaux M, Böhm M. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo‐controlled trial. Eur J Heart Fail 2017 ; 19 : 1495 – 1503.
Gyöngyösi M, Winkler J, Ramos I, Do QT FH, Mc Donald K, González A, Thum T, Díez J, Jaisser F, Pizard A, Zannad F. Myocardial fibrosis: biomedical research from bench to bedside. Eur J Heart Fail 2017 ; 19 : 177 – 191.
Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GY, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM, Zamorano JL, Aboyans V, Achenbach S, Agewall S, Badimon L, Barón‐Esquivias G, Baumgartner H, Bax JJ, Bueno H, Carerj S, Dean V, Erol Ç, Fitzsimons D, Gaemperli O, Kirchhof P, Kolh P, Lancellotti P, Lip GY, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Roffi M, Torbicki A, Vaz Carneiro A, Windecker S. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur J Heart Fail 2017 ; 19 : 9 – 42.
Teerlink JR, Voors AA, Ponikowski P, Pang PS, Greenberg BH, Filippatos G, Felker GM, Davison BA, Cotter G, Gimpelewicz C, Boer‐Martins L, Wernsing M, Hua TA, Severin T, Metra M. Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX‐AHF‐2 study. Eur J Heart Fail 2017 ; 19 : 800 – 809.
Tsuji K, Sakata Y, Nochioka K, Miura M, Yamauchi T, Onose T, Abe R, Oikawa T, Kasahara S, Sato M, Shiroto T, Takahashi J, Miyata S, Shimokawa H. Characterization of heart failure patients with mid‐range left ventricular ejection fraction –a report from the CHART‐2 Study. Eur J Heart Fail 2017 ; 19 : 1258 – 1269.
Gustafsson F, Rogers JG. Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes. Eur J Heart Fail 2017 ; 19 : 595 – 602.
Butler J, Hamo CE, Filippatos G, Pocock SJ, Bernstein RA, Brueckmann M, Cheung AK, George JT, Green JB, Januzzi JL, Kaul S, Lam CS, Lip GY, Marx N, McCullough PA, Mehta CR, Ponikowski P, Rosenstock J, Sattar N, Salsali A, Scirica BM, Shah SJ, Tsutsui H, Verma S, Wanner C, Woerle H, Zannad F, Anker SD. The potential role and rationale for treatment of heart failure with sodium–glucose co‐transporter 2 inhibitors. Eur J Heart Fail 2017 ; 19 : 1390 – 1400.
Targher G, Dauriz M, Laroche C, Temporelli PL, Hassanein M, Seferovic PM, Drozdz J, Ferrari R, Anker S, Coats A, Filippatos G, Crespo‐Leiro MG, Mebazaa A, Piepoli MF, Maggioni AP, Tavazzi L. In‐hospital and 1‐year mortality associated with diabetes in patients with acute heart failure: results from the ESC‐HFA Heart Failure Long‐Term Registry. Eur J Heart Fail 2017 ; 19 : 54 – 65.
Fitchett DH, Udell JA, Inzucchi SE. Heart failure outcomes in clinical trials of glucose‐lowering agents in patients with diabetes. Eur J Heart Fail 2017 ; 19 : 43 – 53.
Chioncel O, Mebazaa A, Harjola V, Coats AJ, Piepoli MF, Crespo‐Leiro MG, Laroche C, Seferovic PM, Anker SD, Ferrari R, Ruschitzka F, Lopez‐Fernandez S, Miani D, Filippatos G, Maggioni AP. Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Fail Long‐Term Registry. Eur J Heart Fail 2017 ; 19 : 1242 – 1254.
Sliwa K, Mebazaa A, Hilfiker‐Kleiner D, Petrie MC, Maggioni AP, Laroche C, Regitz‐Zagrosek V, Schaufelberger M, Tavazzi L, van der Meer P, Roos‐Hesselink JW, Seferovic P, van Spandonck‐Zwarts K, Mbakwem A, Böhm M, Mouquet F, Pieske B, Hall R, Ponikowski P, Bauersachs J. Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM). Eur J Heart Fail 2017 ; 19 : 1131 – 1141.
Ghio S, Guazzi M, Scardovi AB, Klersy C, Clemenza F, Carluccio E, Temporelli PL, Rossi A, Faggiano P, Traversi E, Vriz O, Dini FL. Different correlates but similar prognostic implications for right ventricular dysfunction in heart failure patients with reduced or preserved ejection fraction. Eur J Heart Fail 2017 ; 19 : 873 – 879.
Löfman I, Szummer K, Dahlström U, Jernberg T, Lund LH. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid‐range, and reduced ejection fraction. Eur J Heart Fail 2017 ; 19 : 1606 – 1614.
Meani P, Gelsomino S, Natour E, Johnson DM, Rocca HB, Pappalardo F, Bidar E, Makhoul M, Raffa G, Heuts S, Lozekoot P, Kats S, Sluijpers N, Schreurs R, Delnoij T, Montalti A, Sels JW, van de Poll M, Roekaerts P, Poels T, Korver E, Babar Z, Maessen J, Lorusso R. Modalities and effects of left ventricle unloading on extracorporeal life support: a review of the current literature. Eur J Heart Fail 2017 ; 19 : 84 – 91.
Boriani G, Da Costa A, Quesada A, Ricci RP, Favale S, Boscolo G, Clementy N, Amori V, Mangoni di S Stefano L, Burri H. Effects of remote monitoring on clinical outcomes and use of healthcare resources in heart failure patients with biventricular defibrillators: results of the MORE‐CARE multicentre randomized controlled trial. Eur J Heart Fail 2017 ; 19 : 416 – 425.
Arrigo M, Gaya E, Parenica J, Ishihara S, Zhang J, Choi D, Park JJ, Alhabib KF, Sato N, Miro O, Maggioni AP, Zhang Y, Spinar J, Cohen‐Solal A, Iwashyna TJ, Mebazaa A. Precipitating factors and 90‐day outcome of acute heart failure: a report from the intercontinental GREAT registry. Eur J Heart Fail 2017 ; 19 : 201 – 208.
Meijers WC, van der Velde AR, Muller Kobold AC, Dijck‐Brouwer J, Wu AH, Jaffe A, de Boer RA. Variability of biomarkers in patients with chronic heart failure and healthy controls. Eur J Heart Fail 2017 ; 19 : 357 – 365.
Jansweijer JA, Nieuwhof K, Russo F, Hoorntje ET, Jongbloed JD, Lekanne Deprez RH, Postma AV, Bronk M, van Rijsingen IA, de Haij S, Biagini E, van Haelst PL, van Wijngaarden J, van den Berg MP, Wilde AA, Mannens MM, de Boer RA, van Spaendonck‐Zwarts KY, van Tintelen JP, Pinto YM. Truncating titin mutations are associated with a mild and treatable form of dilated cardiomyopathy. Eur J Heart Fail 2017 ; 19 : 512 – 521.
Devaux Y, Creemers EE, Boon RA, Werfel S, Thum T, Engelhardt S, Dimmeler S, Squire I. Circular RNAs in heart failure. Eur J Heart Fail 2017 ; 19 : 701 – 709.
Niewinski P, Janczak D, Rucinski A, Tubek S, Engelman ZJ, Piesiak P, Jazwiec P, Banasiak W, Fudim M, Sobotka PA, Javaheri S, Hart EC, Paton JF, Ponikowski P. Carotid body resection for sympathetic modulation in systolic heart failure: results from first‐in‐man study. Eur J Heart Fail 2017 ; 19 : 391 – 400.
Harjola V, Mullens W, Banaszewski M, Bauersachs J, Brunner‐La Rocca H, Chioncel O, Collins SP, Doehner W, Filippatos GS, Flammer AJ, Fuhrmann V, Lainscak M, Lassus J, Legrand M, Masip J, Mueller C, Papp Z, Parissis J, Platz E, Rudiger A, Ruschitzka F, Schäfer A, Seferovic PM, Skouri H, Yilmaz MB, Mebazaa A. Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail 2017 ; 19 : 821 – 836.
Cannon JA, Shen L, Jhund PS, Kristensen SL, Køber L, Chen F, Gong J, Lefkowitz MP, Rouleau JL, Shi VC, Swedberg K, Zile MR, Solomon SD, Packer M, McMurray JJ ; PARADIGM‐HF Investigators and Committees Dementia‐related adverse events in PARADIGM‐HF and other trials in heart failure with reduced ejection fraction. Eur J Heart Fail 2017 ; 19 : 129 – 137.
Seferović PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, Paulus WJ, Komajda M, Cosentino F, de Boer RA, Farmakis D, Doehner W, Lambrinou E, Lopatin Y, Piepoli MF, Theodorakis MJ, Wiggers H, Lekakis J, Mebazaa A, Mamas MA, Tschöpe C, Hoes AW, Seferović JP, Logue J, McDonagh T, Riley JP, Milinković I, Polovina M, van Veldhuisen DJ, Lainscak M, Maggioni AP, Ruschitzka F, McMurray JJ. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2018 ; 20 : 853 – 872.
Anker SD, Kirwan B, van Veldhuisen DJ, Filippatos G, Comin‐Colet J, Ruschitzka F, Lüscher TF, Arutyunov GP, Motro M, Mori C, Roubert B, Pocock SJ, Ponikowski P. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron‐deficient heart failure patients: an individual patient data meta‐analysis. Eur J Heart Fail 2018 ; 20 : 125 – 133.
Lund LH, Claggett B, Liu J, Lam CS, Jhund PS, Rosano GM, Swedberg K, Yusuf S, Granger CB, Pfeffer MA, McMurray JJ, Solomon SD. Heart failure with mid‐range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail 2018 ; 20 : 1230 – 1239.
Palazzini M, Dardi F, Manes A, Bacchi Reggiani ML, Gotti E, Rinaldi A, Albini A, Monti E, Galiè N. Pulmonary hypertension due to left heart disease: analysis of survival according to the haemodynamic classification of the 2015 ESC/ERS guidelines and insights for future changes. Eur J Heart Fail 2018 ; 20 : 248 – 255.
Hoes MF, Grote Beverborg N, Kijlstra JD, Kuipers J, Swinkels DW, Giepmans BN, Rodenburg RJ, van Veldhuisen DJ, de Boer RA, van der Meer P. Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function. Eur J Heart Fail 2018 ; 20 : 910 – 919.
Gorter TM, van Veldhuisen DJ, Bauersachs J, Borlaug BA, Celutkiene J, Coats AJ, Crespo‐Leiro MG, Guazzi M, Harjola V, Heymans S, Hill L, Lainscak M, Lam CS, Lund LH, Lyon AR, Mebazaa A, Mueller C, Paulus WJ, Pieske B, Piepoli MF, Ruschitzka F, Rutten FH, Seferovic PM, Solomon SD, Shah SJ, Triposkiadis F, Wachter R, Tschöpe C, de Boer RA. Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2018 ; 20 : 16 – 37.
Merlo M, Cannatà A, Gobbo M, Stolfo D, Elliott PM, Sinagra G. Evolving concepts in dilated cardiomyopathy. Eur J Heart Fail 2018 ; 20 : 228 – 239.
Agostoni P, Paolillo S, Mapelli M, Gentile P, Salvioni E, Veglia F, Bonomi A, Corrà U, Lagioia R, Limongelli G, Sinagra G, Cattadori G, Scardovi AB, Metra M, Carubelli V, Scrutinio D, Raimondo R, Emdin M, Piepoli M, Magrì D, Parati G, Caravita S, Re F, Cicoira M, Minà C, Correale M, Frigerio M, Bussotti M, Oliva F, Battaia E, Belardinelli R, Mezzani A, Pastormerlo L, Guazzi M, Badagliacca R, Di Lenarda A, Passino C, Sciomer S, Zambon E, Pacileo G, Ricci R, Apostolo A, Palermo P, Contini M, Clemenza F, Marchese G, Gargiulo P, Binno S, Lombardi C, Passantino A, Perrone Filardi P. Multiparametric prognostic scores in chronic heart failure with reduced ejection fraction: a long‐term comparison. Eur J Heart Fail 2018 ; 20 : 700 – 710.
Doehner W, Ural D, Haeusler KG, Čelutkienė J, Bestetti R, Cavusoglu Y, Peña‐Duque MA, Glavas D, Iacoviello M, Laufs U, Alvear RM, Mbakwem A, Piepoli MF, Rosen SD, Tsivgoulis G, Vitale C, Yilmaz MB, Anker SD, Filippatos G, Seferovic P, Coats AJ, Ruschitzka F. Heart and brain interaction in patients with heart failure: overview and proposal for a taxonomy. A position paper from the Study Group on Heart and Brain Interaction of the Heart Failure Association. Eur J Heart Fail 2018 ; 20 : 199 – 215.
Canepa M, Straburzynska‐Migaj E, Drozdz J, Fernandez‐Vivancos C, Pinilla JM, Nyolczas N, Temporelli PL, Mebazaa A, Lainscak M, Laroche C, Maggioni AP, Piepoli MF, Coats AJ, Ferrari R, Tavazzi L. Characteristics, treatments and 1‐year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long‐Term Registry. Eur J Heart Fail 2018 ; 20 : 100 – 110.
Van Aelst LN, Arrigo M, Placido R, Akiyama E, Girerd N, Zannad F, Manivet P, Rossignol P, Badoz M, Sadoune M, Launay J, Gayat E, Lam CS, Cohen‐Solal A, Mebazaa A, Seronde M. Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion. Eur J Heart Fail 2018 ; 20 : 738 – 747.
Geis NA, Puls M, Lubos E, Zuern CS, Franke J, Schueler R, von Bardeleben RS, Boekstegers P, Ouarrak T, Zahn R, Ince H, Senges J, Katus HA, Bekeredjian R. Safety and efficacy of MitraClip™ therapy in patients with severely impaired left ventricular ejection fraction: results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail 2018 ; 20 : 598 – 608.
Wolsk E, Claggett B, Køber L, Pocock S, Yusuf S, Swedberg K, McMurray JJ, Granger CB, Pfeffer MA, Solomon SD. Contribution of cardiac and extra‐cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. Eur J Heart Fail 2018 ; 20 : 504 – 510.
Gupta A, Fonarow GC. The Hospital Readmissions Reduction Program –learning from failure of a healthcare policy. Eur J Heart Fail 2018 ; 20 : 1169 – 1174.
Crespo‐Leiro MG, Metra M, Lund LH, Milicic D, Costanzo MR, Filippatos G, Gustafsson F, Tsui S, Barge‐Caballero E, De Jonge N, Frigerio M, Hamdan R, Hasin T, Hülsmann M, Nalbantgil S, Potena L, Bauersachs J, Gkouziouta A, Ruhparwar A, Ristic AD, Straburzynska‐Migaj E, McDonagh T, Seferovic P, Ruschitzka F. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2018 ; 20 : 1505 – 1535.
Corrà U, Agostoni PG, Anker SD, Coats AJ, Crespo‐Leiro MG, de Boer RA, Harjola V, Hill L, Lainscak M, Lund LH, Metra M, Ponikowski P, Riley J, Seferović PM, Piepoli MF. Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2018 ; 20 : 3 – 15.
Ameri P, Canepa M, Anker MS, Belenkov Y, Bergler‐Klein J, Cohen‐Solal A, Farmakis D, López‐Fernández T, Lainscak M, Pudil R, Ruschitska F, Seferovic P, Filippatos G, Coats A, Suter T, Von Haehling S, Ciardiello F, de Boer RA, Lyon AR, Tocchetti CG. Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. Eur J Heart Fail 2018 ; 20 : 879 – 887.
Cosmi F, Shen L, Magnoli M, Abraham WT, Anand IS, Cleland JG, Cohn JN, Cosmi D, De Berardis G, Dickstein K, Franzosi MG, Gullestad L, Jhund PS, Kjekshus J, Køber L, Lepore V, Lucisano G, Maggioni AP, Masson S, McMurray JJ, Nicolucci A, Petrarolo V, Robusto F, Staszewsky L, Tavazzi L, Teli R, Tognoni G, Wikstrand J, Latini R. Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. Eur J Heart Fail 2018 ; 20 : 888 – 895.
van Boven N, Kardys I, van Vark LC, Akkerhuis KM, de Ronde MW, Khan MA, Merkus D, Liu Z, Voors AA, Asselbergs FW, van den Bos E, Boersma E, Hillege H, Duncker DJ, Pinto YM, Postmus D. Serially measured circulating microRNAs and adverse clinical outcomes in patients with acute heart failure. Eur J Heart Fail 2018 ; 20 : 89 – 96.
Gayat E, Arrigo M, Littnerova S, Sato N, Parenica J, Ishihara S, Spinar J, Müller C, Harjola V, Lassus J, Miró Ò, Maggioni AP, AlHabib KF, Choi D, Park JJ, Zhang Y, Zhang J, Januzzi JL, Kajimoto K, Cohen‐Solal A, Mebazaa A. Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity‐score matched study. Eur J Heart Fail 2018 ; 20 : 345 – 354.
Bayés‐Genis A, Lanfear DE, de Ronde MW, Lupón J, Leenders JJ, Liu Z, Zuithoff NP, Eijkemans MJ, Zamora E, De Antonio M, Zwinderman AH, Pinto‐Sietsma S, Pinto YM. Prognostic value of circulating microRNAs on heart failure‐related morbidity and mortality in two large diverse cohorts of general heart failure patients. Eur J Heart Fail 2018 ; 20 : 67 – 75.
Sokoreli I, Pauws SC, Steyerberg EW, de Vries G, Riistama JM, Tesanovic A, Kazmi S, Pellicori P, Cleland JG, Clark AL. Prognostic value of psychosocial factors for first and recurrent hospitalizations and mortality in heart failure patients: insights from the OPERA‐HF study. Eur J Heart Fail 2018 ; 20 : 689 – 696.
Stenemo M, Nowak C, Byberg L, Sundström J, Giedraitis V, Lind L, Ingelsson E, Fall T, Ärnlöv J. Circulating proteins as predictors of incident heart failure in the elderly. Eur J Heart Fail 2018 ; 20 : 55 – 62.
Masson S, Batkai S, Beermann J, Bär C, Pfanne A, Thum S, Magnoli M, Balconi G, Nicolosi GL, Tavazzi L, Latini R, Thum T. Circulating microRNA‐132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure. Eur J Heart Fail 2018 ; 20 : 78 – 85.
Dickstein K, Normand C, Auricchio A, Bogale N, Cleland JG, Gitt AK, Stellbrink C, Anker SD, Filippatos G, Gasparini M, Hindricks G, Blomström Lundqvist C, Ponikowski P, Ruschitzka F, Botto GL, Bulava A, Duray G, Israel C, Leclercq C, Margitfalvi P, Cano Ó, Plummer C, Sarigul NU, Sterlinski M, Linde C. CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patients –who is doing what to whom and how? Eur J Heart Fail 2018 ; 20 : 1039 – 1051.
Kotseva K, Wood D, De Bacquer D, De Backer G, Rydén L, Jennings C, Gyberg V, Amouyel P, Bruthans J, Castro Conde A, Cífková R, Deckers JW, De Sutter J, Dilic M, Dolzhenko M, Erglis A, Fras Z, Gaita D, Gotcheva N, Goudevenos J, Heuschmann P, Laucevicius A, Lehto S, Lovic D, Miličić D, Moore D, Nicolaides E, Oganov R, Pajak A, Pogosova N, Reiner Z, Stagmo M, Störk S, Tokgözoğlu L, Vulic D. EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 2016 ; 23 : 636 – 648.
Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corrà U, Cosyns B, Deaton C, Graham I, Hall MS, FD H, Løchen ML, Löllgen H, Marques‐Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, WM V, Binno S ; ESC Scientific Document Group 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol 2016 ; 23 : NP1 – NP96.
Eckel N, Meidtner K, Kalle‐Uhlmann T, Stefan N, Schulze MB. Metabolically healthy obesity and cardiovascular events: a systematic review and meta‐analysis. Eur J Prev Cardiol 2016 ; 23 : 956 – 966.
Kotseva K, De Bacquer D, De Backer G, Rydén L, Jennings C, Gyberg V, Abreu A, Aguiar C, Conde AC, Davletov K, Dilic M, Dolzhenko M, Gaita D, Georgiev B, Gotcheva N, Lalic N, Laucevicius A, Lovic D, Mancas S, Miličić D, Oganov R, Pajak A, Pogosova N, Reiner Ž, Vulic D, Wood D. Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross‐sectional survey in 14 European regions. Eur J Prev Cardiol 2016 ; 23 : 2007 – 2018.
Friis‐Møller N, Ryom L, Smith C, Weber R, Reiss P, Dabis F, De Wit S, Monforte AD, Kirk O, Fontas E, Sabin C, Phillips A, Lundgren J, Law M. An updated prediction model of the global risk of cardiovascular disease in HIV‐positive persons: the Data‐collection on Adverse effects of Anti‐HIV Drugs (D:A:D) study. Eur J Prev Cardiol 2016 ; 23 : 214 – 223.
Rauch B, Davos CH, Doherty P, Saure D, Metzendorf MI, Salzwedel A, Völler H, Jensen K, Schmid JP ; 'Cardiac Rehabilitation Section', European Association of Preventive Cardiology (EAPC), in cooperation with the Institute of Medical Biometry and Informatics (IMBI), Department of Medical Biometry, University of Heidelberg, and the Cochrane Metabolic and Endocrine Disorders Group, Institute of General Practice, Heinrich‐Heine University, Düsseldorf, Germany The prognostic effect of cardiac rehabilitation in the era of acute revascularisation and statin therapy: a systematic review and meta‐analysis of randomized and non‐randomized studies ‐ The Cardiac Rehabilitation Outcome Study (CROS). Eur J Prev Cardiol 2016 ; 23 : 1914 – 1939.
Price KJ, Gordon BA, Bird SR, Benson AC. A review of guidelines for cardiac rehabilitation exercise programmes: is there an international consensus? Eur J Prev Cardiol 2016 ; 23 : 1715 – 1733.
Bonaccio M, Di Castelnuovo A, Costanzo S, Persichillo M, De Curtis A, Donati MB, de Gaetano G, Lacoviello L. Adherence to the traditional Mediterranean diet and mortality in subjects with diabetes. Prospective results from the MOLI‐SANI study. Eur J Prev Cardiol 2016 ; 23 : 400 – 407.
Roeters van Lennep JE, Heida KY, Bots ML, Hoek A. Cardiovascular disease risk in women with premature ovarian insufficiency: a systematic review and meta‐analysis. Eur J Prev Cardiol 2016 ; 23 : 178 – 186.
Chu P, Gotink RA, Yeh GY, Goldie SJ, Hunink MM. The effectiveness of yoga in modifying risk factors for cardiovascular disease and metabolic syndrome: a systematic review and meta‐analysis of randomized controlled trials. Eur J Prev Cardiol 2016 ; 23 : 291 – 307.
Cooney MT, Selmer R, Lindman A, Tverdal A, Menotti A, Thomsen T, DeBacker G, De Bacquer D, Tell GS, Njolstad I, Graham IM. Cardiovascular risk estimation in older persons: SCORE OP. Eur J Prev Cardiol 2016 ; 23 : 1093 – 1103.
Alharbi M, Bauman A, Neubeck L, Gallagher R. Validation of Fitbit‐Flex as a measure of free‐living physical activity in a community‐based phase III cardiac rehabilitation population. Eur J Prev Cardiol 2016 ; 23 : 1476 – 1485.
Piepoli MF, Corrà U, Dendale P, Frederix I, Prescott E, Schmid JP, Schmid JP, Cupples M, Deaton C, Doherty P, Giannuzzi P, Graham I, Hansen TB, Jennings C, Landmesser U, Marques‐Vidal P, Vrints C, Walker D, Bueno H, Fitzsimons D, Pelliccia A. Challenges in secondary prevention after acute myocardial infarction: a call for action. Eur J Prev Cardiol 2016 ; 23 : 1994 – 2006.
D'Ascenzi F, Caselli S, Solari M, Pelliccia A, Cameli M, Focardi M, Padeletti M, Corrado D, Bonifazi M, Mondillo S. Novel echocardiographic techniques for the evaluation of athletes' heart: a focus on speckle‐tracking echocardiography. Eur J Prev Cardiol 2016 ; 23 : 437 – 446.
Fukuta H, Goto T, Wakami K, Ohte N. Effects of drug and exercise intervention on functional capacity and quality of life in heart failure with preserved ejection fraction: a meta‐analysis of randomized controlled trials. Eur J Prev Cardiol 2016 ; 23 : 78 – 85.
Frederix I, Hansen D, Coninx K, Vandervoort P, Vandijck D, Hens N, Van Craenenbroeck E, Van Driessche N, Dendale P. Effect of comprehensive cardiac telerehabilitation on one‐year cardiovascular rehospitalization rate, medical costs and quality of life: a cost‐effectiveness analysis. Eur J Prev Cardiol 2016 ; 23 : 674 – 682.
Hobbs FR, Taylor CJ, Jan Geersing G, Rutten FH, Brouwer JR ; European Primary Care Cardiovascular Society (EPCCS) SPAF Working Group European Primary Care Cardiovascular Society (EPCCS) consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary care. Eur J Prev Cardiol 2016 ; 23 : 460 – 473.
Pallisgaard JL, Schjerning AM, Lindhardt TB, Procida K, Hansen ML, Torp‐Pedersen C, Gislason GH. Risk of atrial fibrillation in diabetes mellitus: a nationwide cohort study. Eur J Prev Cardiol 2016 ; 23 : 621 – 627.
Solberg E, Borjesson M, Sharma S, Papadakis M, Wilhelm M, Drezner J, Harmon KG, Alonso JM, Heidbuchel H, Dugmore D, Panhuyzen‐Goedkoop NM, Mellwig KP, Carre F, Rasmusen H, Niebauer J, Behr ER, Thiene G, Sheppard MN, Basso C, Corrado D. Sudden cardiac arrest in sports –need for uniform registration: a position paper from the Sport Cardiology Section of the European Association for Cardiovascular Prevention and Rehabilitation. Eur J Prev Cardiol 2016 ; 23 : 657 – 667.
Hall AJ, Stubbs B, Mamas MA, Myint PK, Smith TO. Association between osteoarthritis and cardiovascular disease: systematic review and meta‐analysis. Eur J Prev Cardiol 2016 ; 23 : 938 – 946.
Bohm P, Scharhag J, Meyer T. Data from a nationwide registry on sports‐related sudden cardiac deaths in Germany. Eur J Prev Cardiol 2016 ; 23 : 649 – 656.
Groenewegen K, den Ruijter H, Pasterkamp G, Polak J, Bots M, Peters SA. Vascular age to determine cardiovascular disease risk: a systematic review of its concepts, definitions, and clinical applications. Eur J Prev Cardiol 2016 ; 23 : 264 – 274.
Taggar JS, Coleman T, Lewis S, Heneghan C, Jones M. Accuracy of methods for detecting an irregular pulse and suspected atrial fibrillation: a systematic review and meta‐analysis. Eur J Prev Cardiol 2016 ; 23 : 1330 – 1338.
Pfaeffli Dale L, Dobson R, Whittaker R, Maddison R. The effectiveness of mobile‐health behaviour change interventions for cardiovascular disease self‐management: a systematic review. Eur J Prev Cardiol 2016 ; 23 : 801 – 817.
Heida KY, Bots ML, de Groot CJ, van Dunné FM, Hammoud NM, Hoek A, Laven J, Maas AH, Roeters van Lennep JE, Velthuis BK, Franx A. Cardiovascular risk management after reproductive and pregnancy‐related disorders: a Dutch multidisciplinary evidence‐based guideline. Eur J Prev Cardiol 2016 ; 23 : 1863 – 1879.
Vigorito C, Abreu A, Ambrosetti M, Belardinelli R, Corrà U, Cupples M, Davos CH, Hoefer S, Iliou MC, Schmid JP, Voeller H, Doherty P. Frailty and cardiac rehabilitation: a call to action from the EAPC Cardiac Rehabilitation Section. Eur J Prev Cardiol 2017 ; 24 : 577 – 590.
Mont L, Pelliccia A, Sharma S, Biffi A, Borjesson M, Brugada Terradellas J, Carré F, Guasch E, Heidbuchel H, La Gerche A, Lampert R, McKenna W, Papadakis M, Priori SG, Scanavacca M, Thompson P, Sticherling C, Viskin S, Wilson M, Corrado D, Lip GY, Gorenek B, Blomström Lundqvist C, Merkely B, Hindricks G, Hernández‐Madrid A, Lane D, Boriani G, Narasimhan C, Marquez MF, Haines D, Mackall J, Manuel Marques‐Vidal P, Corra U, Halle M, Tiberi M, Niebauer J, Piepoli M. Pre‐participation cardiovascular evaluation for athletic participants to prevent sudden death: position paper from the EHRA and the EACPR, branches of the ESC. Endorsed by APHRS, HRS, and SOLAECE. Eur J Prev Cardiol 2017 ; 24 : 41 – 69.
Hansen D, Dendale P, Coninx K, Vanhees L, Piepoli MF, Niebauer J, Cornelissen V, Pedretti R, Geurts E, Ruiz GR, Corrà U, Schmid JP, Greco E, Davos CH, Edelmann F, Abreu A, Rauch B, Ambrosetti M, Braga SS, Barna O, Beckers P, Bussotti M, Fagard R, Faggiano P, Garcia‐Porrero E, Kouidi E, Lamotte M, Neunhäuserer D, Reibis R, Spruit MA, Stettler C, Takken T, Tonoli C, Vigorito C, Völler H, Doherty P. The European Association of Preventive Cardiology Exercise Prescription in Everyday Practice and Rehabilitative Training (EXPERT) tool: a digital training and decision support system for optimized exercise prescription in cardiovascular disease. Concept, definitions and construction methodology. Eur J Prev Cardiol 2017 ; 24 : 1017 – 1031.
Sato T, Yoshihisa A, Kanno Y, Suzuki S, Yamaki T, Sugimoto K, Kunii H, Nakazato K, Suzuki H, Saitoh SI, Ishida T, Takeishi Y. Cardiopulmonary exercise testing as prognostic indicators: comparisons among heart failure patients with reduced, mid‐range and preserved ejection fraction. Eur J Prev Cardiol 2017 ; 24 : 1979 – 1987.
Kraal JJ, Van den Akker‐Van Marle ME, Abu‐Hanna A, Stut W, Peek N, Kemps HM. Clinical and cost‐effectiveness of home‐based cardiac rehabilitation compared to conventional, centre‐based cardiac rehabilitation: results of the FIT@Home study. Eur J Prev Cardiol 2017 ; 24 : 1260 – 1273.
Pedersen SS, von Känel R, Tully PJ, Denollet J. Psychosocial perspectives in cardiovascular disease. Eur J Prev Cardiol 2017 ; 24 : 108 – 115.
Frederix I, Solmi F, Piepoli MF, Dendale P. Cardiac telerehabilitation: a novel cost‐efficient care delivery strategy that can induce long‐term health benefits. Eur J Prev Cardiol 2017 ; 24 : 1708 – 1717.
Gorenek B, Pelliccia A, Benjamin EJ, Boriani G, Crijns HJ, Fogel RI, van Gelder IC, Halle M, Kudaiberdieva G, Lane DA, Bjerregaard Larsen T, Lip GY, Løchen ML, Marin F, Niebauer J, Sanders P, Tokgozoglu L, Vos MA, van Wagoner DR, Fauchier L, Savelieva I, Goette A, Agewall S, Chiang CE, Figueiredo M, Stiles M, Dickfeld T, Patton K, Piepoli M, Corra U, Manuel Marques‐Vidal P, Faggiano P, Schmid JP, Abreu A. European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). Eur J Prev Cardiol 2017 ; 24 : 4 – 40.
Pogosova N, Kotseva K, de Bacquer D, von Känel R, de Smedt D, Bruthans J, Dolzhenko M. Psychosocial risk factors in relation to other cardiovascular risk factors in coronary heart disease: results from the EUROASPIRE IV survey. A registry from the European Society of Cardiology. Eur J Prev Cardiol 2017 ; 24 : 1371 – 1380.
Coppetti T, Brauchlin A, Müggler S, Attinger‐Toller A, Templin C, Schönrath F, Hellermann J, Lüscher TF, Biaggi P, Wyss CA. Accuracy of smartphone apps for heart rate measurement. Eur J Prev Cardiol 2017 ; 24 : 1287 – 1293.
Ruddox V, Sandven I, Munkhaugen J, Skattebu J, Edvardsen T, Otterstad JE. Atrial fibrillation and the risk for myocardial infarction, all‐cause mortality and heart failure: a systematic review and meta‐analysis. Eur J Prev Cardiol 2017 ; 24 : 1555 – 1566.
Ribeiro GS, Melo RD, Deresz LF, Dal Lago P, Pontes MR, Karsten M. Cardiac rehabilitation programme after transcatheter aortic valve implantation versus surgical aortic valve replacement: systematic review and meta‐analysis. Eur J Prev Cardiol 2017 ; 24 : 688 – 697.
Maiorino MI, Bellastella G, Petrizzo M, Gicchino M, Caputo M, Giugliano D, Esposito K. Effect of a Mediterranean diet on endothelial progenitor cells and carotid intima‐media thickness in type 2 diabetes: follow‐up of a randomized trial. Eur J Prev Cardiol 2017 ; 24 : 399 – 408.
Eichler S, Salzwedel A, Reibis R, Nothroff J, Harnath A, Schikora M, Butter C, Wegscheider K, Völler H. Multicomponent cardiac rehabilitation in patients after transcatheter aortic valve implantation: predictors of functional and psychocognitive recovery. Eur J Prev Cardiol 2017 ; 24 : 257 – 264.
Pećin I, Hartgers ML, Hovingh GK, Dent R, Reiner Ž. Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: the role of PCSK9 inhibitors. Eur J Prev Cardiol 2017 ; 24 : 1383 – 1401.
Schiele F, Ecarnot F, Chopard R. Coronary artery disease: risk stratification and patient selection for more aggressive secondary prevention. Eur J Prev Cardiol 2017 ; 24 : 88 – 100.
Claes J, Buys R, Budts W, Smart N, Cornelissen VA. Longer‐term effects of home‐based exercise interventions on exercise capacity and physical activity in coronary artery disease patients: a systematic review and meta‐analysis. Eur J Prev Cardiol 2017 ; 24 : 244 – 256.
Aaby A, Friis K, Christensen B, Rowlands G, Maindal HT. Health literacy is associated with health behaviour and self‐reported health: a large population‐based study in individuals with cardiovascular disease. Eur J Prev Cardiol 2017 ; 24 : 1880 – 1888.
Huang W, Resch S, Oliveira RK, Cockrill BA, Systrom DM, Waxman AB. Invasive cardiopulmonary exercise testing in the evaluation of unexplained dyspnea: insights from a multidisciplinary dyspnea center. Eur J Prev Cardiol 2017 ; 24 : 1190 – 1199.
Mundal L, Igland J, Ose L, Holven KB, Veierød MB, Leren TP, Retterstøl K. Cardiovascular disease mortality in patients with genetically verified familial hypercholesterolemia in Norway during 1992–2013. Eur J Prev Cardiol 2017 ; 24 : 137 – 144.
Koolhaas CM, Dhana K, Schoufour JD, Ikram MA, Kavousi M, Franco OH. Impact of physical activity on the association of overweight and obesity with cardiovascular disease: the Rotterdam Study. Eur J Prev Cardiol 2017 ; 24 : 934 – 941.
Eyles H, McLean R, Nea B, Jiang Y, Doughty RN, McLean R, Ni Mhurchu C. A salt‐reduction smartphone app supports lower‐salt food purchases for people with cardiovascular disease: findings from the SaltSwitch randomised controlled trial. Eur J Prev Cardiol 2017 ; 24 : 1435 – 1444.
He Q, Zhang P, Li G, Dai H, Shi J. The association between insomnia symptoms and risk of cardio‐cerebral vascular events: a meta‐analysis of prospective cohort studies. Eur J Prev Cardiol 2017 ; 24 : 1071 – 1082.
Gomes‐Neto M, Durães AR, Reis HF, Neves VR, Martinez BP, Carvalho VO. High‐intensity interval training versus moderate‐intensity continuous training on exercise capacity and quality of life in patients with coronary artery disease: a systematic review and meta‐analysis. Eur J Prev Cardiol 2017 ; 24 : 1696 – 1707.
Vasankari V, Husu P, Vähä‐Ypyä H, Suni J, Tokola K, Halonen J, Hartikainen J, Sievänen H, Vasankari T. Association of objectively measured sedentary behaviour and physical activity with cardiovascular disease risk. Eur J Prev Cardiol 2017 ; 24 : 1311 – 1318.
Kotseva K, Wood D, De Bacquer D. Determinants of participation and risk factor control according to attendance in cardiac rehabilitation programmes in coronary patients in Europe: EUROASPIRE IV survey. Eur J Prev Cardiol 2018 ; 25 : 1242 – 1251.
Coorey GM, Neubeck L, Mulley J, Redfern J. Effectiveness, acceptability and usefulness of mobile applications for cardiovascular disease self‐management: systematic review with meta‐synthesis of quantitative and qualitative data. Eur J Prev Cardiol 2018 ; 25 : 505 – 521.
Lee E, Laukkanen T, Kunutsor SK, Khan H, Willeit P, Zaccardi F, Laukkanen JA. Sauna exposure leads to improved arterial compliance: findings from a non‐randomised experimental study. Eur J Prev Cardiol 2018 ; 25 : 130 – 138.
Jørgensen ME, Andersson C, Vasan RS, Køber L, Abdulla J. Characteristics and prognosis of heart failure with improved compared with persistently reduced ejection fraction: a systematic review and meta‐analyses. Eur J Prev Cardiol 2018 ; 25 : 366 – 376.
Mancusi C, Losi MA, Izzo R, Canciello G, Carlino MV, Albano G, De Luca N, Trimarco B, de Simone G. Higher pulse pressure and risk for cardiovascular events in patients with essential hypertension: the Campania Salute Network. Eur J Prev Cardiol 2018 ; 25 : 235 – 243.
Marmelo F, Rocha V, Moreira‐Gonçalves D. The impact of prehabilitation on post‐surgical complications in patients undergoing non‐urgent cardiovascular surgical intervention: systematic review and meta‐analysis. Eur J Prev Cardiol 2018 ; 25 : 404 – 417.
Tuñón J, Bäck M, Badimón L, Bochaton‐Piallat ML, Cariou B, Daemen MJ, Egido J, Evans PC, Francis SE, Ketelhuth DF, Lutgens E, Matter CM, Monaco C, Steffens S, Stroes E, Vindis C, Weber C, Hoefer IE. Interplay between hypercholesterolaemia and inflammation in atherosclerosis: translating experimental targets into clinical practice. Eur J Prev Cardiol 2017 ; 25 : 948 – 955.
Richards SH, Anderson L, Jenkinson CE, Whalley B, Rees K, Davies P, Bennett P, Liu Z, West R, Thompson DR, Taylor RS. Psychological interventions for coronary heart disease: Cochrane systematic review and meta‐analysis. Eur J Prev Cardiol 2018 ; 25 : 247 – 259.
Aune D, Schlesinger S, Norat T, Riboli E. Tobacco smoking and the risk of atrial fibrillation: a systematic review and meta‐analysis of prospective studies. Eur J Prev Cardiol 2018 ; 25 : 1437 – 1451.
Munkhaugen J, Otterstad JE, Dammen T, Gjertsen E, Moum T, Husebye E, Gullestad L. The prevalence and predictors of elevated C‐reactive protein after a coronary heart disease event. Eur J Prev Cardiol 2018 ; 25 : 923 – 931.
Danchin N, Almahmeed W, Al‐Rasadi K, Azuri J, Berrah A, Cuneo CA, Karpov Y, Kaul U, Kayíkçíoğlu M, Mitchenko O, Ruiz AJ, Aguilar Salinas CA, Santos RD, Mercier F, Blom D. Achievement of low‐density lipoprotein cholesterol goals in 18 countries outside Western Europe: the International ChoLesterol management Practice Study (ICLPS). Eur J Prev Cardiol 2018 ; 25 : 1087 – 1094.
Hagger MS, Hardcastle SJ, Hu M, Kwok S, Lin J, Nawawi HM, Pang J, Santos RD, Soran H, Su TC, Tomlinson B, Watts GF. Health literacy in familial hypercholesterolemia: a cross‐national study. Eur J Prev Cardiol 2018 ; 25 : 936 – 943.
Usman MS, Siddiqi TJ, Memon MM, Khan MS, Rawasia WF, Talha Ayub M, Sreenivasan J, Golzar Y. Sodium‐glucose co‐transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta‐analysis. Eur J Prev Cardiol 2018 ; 25 : 495 – 502.
Lachman S, Boekholdt SM, Luben RN, Sharp SJ, Brage S, Khaw KT, Peters RJ, Wareham NJ. Impact of physical activity on the risk of cardiovascular disease in middle‐aged and older adults: EPIC Norfolk prospective population study. Eur J Prev Cardiol 2018 ; 25 : 200 – 208.
de Waard AK, Wändell PE, Holzmann MJ, Korevaar JC, Hollander M, Gornitzki C, de Wit NJ, Schellevis FG, Lionis C, Søndergaard J, Seifert B, Carlsson AC. Barriers and facilitators to participation in a health check for cardiometabolic diseases in primary care: a systematic review. Eur J Prev Cardiol 2018 ; 25 : 1326 – 1340.
Häcker AL, Reiner B, Oberhoffer R, Hager A, Ewert P, Müller J. Increased arterial stiffness in children with congenital heart disease. Eur J Prev Cardiol 2018 ; 25 : 103 – 109.
Eindhoven DC, Hilt AD, Zwaan TC, Schalij MJ, Borleffs CJ. Age and gender differences in medical adherence after myocardial infarction: women do not receive optimal treatment –The Netherlands claims database. Eur J Prev Cardiol 2018 ; 25 : 181 – 189.
Hansen D, Rovelo Ruiz G, Doherty P, Iliou MC, Vromen T, Hinton S, Frederix I, Wilhelm M, Schmid JP, Abreu A, Ambrosetti M, Garcia‐Porrero E, Coninx K, Dendale P. Do clinicians prescribe exercise similarly in patients with different cardiovascular diseases? Findings from the EAPC EXPERT working group survey. Eur J Prev Cardiol 2018 ; 25 : 682 – 691.
Vidale S, Campana C. Ambient air pollution and cardiovascular diseases: from bench to bedside. Eur J Prev Cardiol 2018 ; 25 : 818 – 825.
Gorostegi‐Anduaga I, Corres P, MartinezAguirre‐Betolaza A, Pérez‐Asenjo J, Aispuru GR, Fryer SM, Maldonado‐Martín S. Effects of different aerobic exercise programmes with nutritional intervention in sedentary adults with overweight/obesity and hypertension: EXERDIET‐HTA study. Eur J Prev Cardiol 2018 ; 25 : 343 – 353.
Zenti MG, Altomari A, Lupo MG, Botta M, Bonora E, Corsini A, Ruscica M, Ferri N. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: impact on low‐density lipoprotein cholesterol and C‐reactive protein levels in cardiovascular disease patients. Eur J Prev Cardiol 2018 ; 25 : 1843 – 1851.
Baert A, De Smedt D, De Sutter J, De Bacquer D, Puddu PE, Clays E, Pardaens S. Factors associated with health‐related quality of life in stable ambulatory congestive heart failure patients: systematic review. Eur J Prev Cardiol 2018 ; 25 : 472 – 481.
Morseth B, Løchen ML, Ariansen I, Myrstad M, Thelle DS. The ambiguity of physical activity, exercise and atrial fibrillation. Eur J Prev Cardiol 2018 ; 25 : 624 – 636.
Doletsky A, Andreev D, Giverts I, Svet A, Brand A, Kuklina M, Sedov V, Dikur O, Syrkin A, Saner H. Interval training early after heart failure decompensation is safe and improves exercise tolerance and quality of life in selected patients. Eur J Prev Cardiol 2018 ; 25 : 9 – 18.
Schwarz V, Düsing P, Liman T, Werner C, Herm J, Bachelier K, Krüll M, Brechtel L, Jungehulsing GJ, Haverkamp W, Böhm M, Endres M, Haeusler KG, Laufs U. Marathon running increases circulating endothelial‐ and thrombocyte‐derived microparticles. Eur J Prev Cardiol 2018 ; 25 : 317 – 324.
Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, Jaarsma T, Krum H, Rastogi V, Rohde LE, Samal UC, Shimokawa H, Budi Siswanto B, Sliwa K, Filippatos G. Heart failure: preventing disease and death worldwide. ESC Heart Fail 2014 ; 1 : 4 – 25.
Cowie MR, Anker SD, Cleland JG, Felker GM, Filippatos G, Jaarsma T, Jourdain P, Knight E, Massie B, Ponikowski P, López‐Sendón J. Improving care for patients with acute heart failure: before, during and after hospitalization. ESC Heart Fail 2014 ; 1 : 110 – 145.
Lam CS. Heart failure in Southeast Asia: facts and numbers. ESC Heart Fail 2015 ; 2 : 46 – 49.
Ponikowski P, Veldhuisen DJ, Comin‐Colet J, Ertl G, Komajda M, Mareev V, McDonagh TA, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD. Rationale and design of the CONFIRM‐HF study: a double‐blind, randomized, placebo‐controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. ESC Heart Fail 2014 ; 1 : 52 – 58.
Haghikia A, Röntgen P, Vogel‐Claussen J, Schwab J, Westenfeld R, Ehlermann P, Berliner D, Podewski E, Hilfiker‐Kleiner D, Bauersachs J. Prognostic implication of right ventricular involvement in peripartum cardiomyopathy: a cardiovascular magnetic resonance study. ESC Heart Fail 2015 ; 2 : 139 – 149.
Maggioni AP, Anker SD, Dahlström U, Filippatos G, Ponikowski P, Zannad F, Amir O, Chioncel O, Crespo‐Leiro M, Drozdz J, Erglis A, Fazlibegovic E, Fonseca C, Fruhwald F, Gatzov P, Goncalvesova E, Hassanein M, Hradec J, Kavoliuniene A, Lainscak M, Logeart D, Merkely B, Metra M, Persson H, Seferovic P, Temizhan A, Tousoulis D, Tavazzi L. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Fail Long‐Term Registry. Eur J Heart Fail 2013 ; 15 : 1173 – 1184.
Maggioni AP, Dahlström U, Filippatos G, Chioncel O, Crespo‐Leiro M, Drozdz J, Fruhwald F, Gullestad L, Logeart D, Fabbri G, Urso R, Metra M, Parissis J, Persson H, Ponikowski P, Rauchhaus M, Voors AA, Nielsen OW, Zannad F, Tavazzi L. EURObservational Research Programme: regional differences and 1‐year follow‐up results of the Heart Failure Pilot Survey (ESC‐HF Pilot). Eur J Heart Fail 2013 ; 15 : 808 – 817.
Mebazaa A, Yilmaz MB, Levy P, Ponikowski P, Peacock WF, Laribi S, Ristic AD, Lambrinou E, Masip J, Riley JP, McDonagh T, Mueller C, de Filippi C, Harjola V, Thiele H, Piepoli MF, Metra M, Maggioni A, McMurray J, Dickstein K, Damman K, Seferovic PM, Ruschitzka F, Leite‐Moreira AF, Bellou A, Anker SD, Filippatos G. Recommendations on pre‐hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur J Heart Fail 2015 ; 17 : 544 – 558.
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau J, Shi VC, Solomon SD, Swedberg K, Zile MR. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin‐converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF). Eur J Heart Fail 2013 ; 15 : 1062 – 1073.
van Deursen VM, Urso R, Laroche C, Damman K, Dahlström U, Tavazzi L, Maggioni AP, Voors AA. Co‐morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail 2014 ; 16 : 103 – 111.
Zarrinkoub R, Wettermark B, Wändell P, Mejhert M, Szulkin R, Ljunggren G, Kahan T. The epidemiology of heart failure, based on data for 21 million inhabitants in Sweden. Eur J Heart Fail 2013 ; 15 : 995 – 1002.
Abudiab MM, Redfield MM, Melenovsky V, Olson TP, Kass DA, Johnson BD, Borlaug BA. Cardiac output response to exercise in relation to metabolic demand in heart failure with preserved ejection fraction. Eur J Heart Fail 2013 ; 15 : 776 – 785.
Piepoli MF, Corrà U, Adamopoulos S, Benzer W, Bjarnason‐Wehrens B, Cupples M, Dendale P, Doherty P, Gaita D, Höfer S, McGee H, Mendes M, Niebauer J, Pogosova N, Garcia‐Porrero E, Rauch B, Schmid JP, Giannuzzi P. Secondary prevention in the clinical management of patients with cardiovascular diseases. Core components, standards and outcome measures for referral and delivery: a Policy Statement from the Cardiac Rehabilitation Section of the European Association for Cardiovascular Prevention & Rehabilitation. Endorsed by the Committee for Practice Guidelines of the European Society of Cardiology. Eur J Prev Cardiol 2014 ; 21 : 664 – 681.
Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvänne M, Scholte Op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F, Bax J, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck‐Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol 2012 ; 19 : 585 – 667.
Sofi F, Cesari F, Casini A, Macchi C, Abbate R, Gensini GF. Insomnia and risk of cardiovascular disease: a meta‐analysis. Eur J Prev Cardiol 2014 ; 21 : 57 – 64.
Molmen‐Hansen HE, Stolen T, Tjonna AE, Aamot IL, Ekeberg IS, Tyldum GA, Wisloff U, Ingul CB, Stoylen A. Aerobic interval training reduces blood pressure and improves myocardial function in hypertensive patients. Eur J Prev Cardiol 2012 ; 19 : 151 – 160.
Vanhees L, De Sutter J, Geladas N, Doyle F, Prescott E, Cornelissen V, Kouidi E, Dugmore D, Vanuzzo D, Börjesson M, Doherty P. Importance of characteristics and modalities of physical activity and exercise in defining the benefits to cardiovascular health within the general population: recommendations from the EACPR (Part I). Eur J Prev Cardiol 2012 ; 19 : 670 – 686.
Mezzani A, Hamm LF, Jones AM, McBride PE, Moholdt T, Stone JA, Urhausen A, Williams MA. Aerobic exercise intensity assessment and prescription in cardiac rehabilitation: a joint position statement of the European Association for Cardiovascular Prevention and Rehabilitation, the American Association of Cardiovascular and Pulmonary Rehabilitation and the Canadian Association of Cardiac Rehabilitation. Eur J Prev Cardiol 2013 ; 20 : 442 – 467.
Neubeck L, Freedman SB, Clark AM, Briffa T, Bauman A, Redfern J. Participating in cardiac rehabilitation: a systematic review and meta‐synthesis of qualitative data. Eur J Prev Cardiol 2012 ; 19 : 494 – 503.
Finegold JA, Manisty CH, Goldacre B, Barron AJ, Francis DP. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo‐controlled trials to aid individual patient choice. Eur J Prev Cardiol 2014 ; 21 : 464 – 474.
]
By Markus S. Anker; Stephan Haehling; Zoltán Papp and Stefan D. Anker
Reported by Author; Author; Author; Author
